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Abstract
Although schizophrenia is traditionally viewed as an illness with a very poor
prognosis, research over the last few years indicates that early intervention may
substantially improve the long-term outcome of this disorder. Several studies
suggest that patients with first-episode psychosis (FEP) are more sensitive to,
and require lower doses of antipsychotic medications than patients with more
chronic forms of illness. However, the optimal dose of first-generation
anti psychotics in patients with FEP has not been explored extensively and
continues to be a controversial subject. This study evaluated the efficacy and
safety of low-dose haloperidol in a South African cohort with FEP.
The study was conducted in two phases:
Phase 1 was an open-label, naturalistic study of 57 subjects with FEP who were
commenced on 1mg of haloperidol for 4 weeks, after which gradual escalation of
doses were allowed, if required. Subjects who failed to respond at haloperidol
10mg per day were switched to thioridazine. Failure to respond to thioridazine
600mg per day was interpreted to indicate treatment resistance. These subjects
were then commenced on clozapine. The principal finding of this phase of the
study was that the majority of subjects could be stabilized and maintained on
very low doses of haloperidol (1.7 ± 1.0 mg/day at 12 months and 1.3 ±0.8
mg/day at 24 months). Ratings for extra-pyramidal side-effects did not increase
significantly from baseline over the duration of the study, except in the case of
tardive dyskinesia (TD), where a substantial number of subjects (12.3%)
developed TD within 12 months of starting treatment.
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Phase 2 of the study was a double-blind, randomized controlled trial of low-dose
(2mg/day) versus "standard dose" (8mg Iday) haloperidol. Forty subjects were
included in this phase of the study; 20 in each treatment arm. The main finding
was that there were no significant differences in treatment reponse between the
two treatment groups. There were, however, significant differences between the
two treatment groups in extrapyramidal side effects (EPSE), with the 8mg per
day group exhibiting significantly higher levels of EPSE than the 2mg per day
group. This was manifested by significant differences in scores on the
Extrapyramidal Symptom Rating Scale (ESRS) and the Simpson-Angus Rating
Scale. Furthermore, subjects in the 8mg haloperidol per day group required
significantly higher doses of anticholinergic medication and had significantly
higher mean levels of prolactin at the end of the study period.
This study indicates that a majority of subjects with first-episode psychosis can
be treated and maintained successfully with very low doses of haloperidol. It also
shows that low-dose treatment is as effective as, and better tolerated than,
"standard" doses. Despite the success with the low-dose treatment, however,
there was still a much higher than expected incidence of tardive dyskinesia, a
serious and potentially irreversible side-effect of neuroleptic treatment.
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Abstrak
Hoewel skisofrenie tradisioneel gesien is as 'n siekte met 'n uiters swak
prognose, dui navorsing oor die afgelope jare daarop dat vroeë ingryping
die langtermynuitkoms van hierdie toestand drasties mag verbeter. Resultate van
verskeie studies dui daarop dat pasiënte met eerste-episode psigose (EEP) nie
net meer sensitief is vir antipsigotiese middels nie, maar ook laer dosisse
daarvan benodig tydens behandeling as pasiënte met meer kroniese vorms van
psigotiese siekte. Desondanks is die kwessie van die korrekte dosis van eerste
generasie antipsigotika in hierdie groep nog onvolledig nagevors en bly dit 'n
omstrede onderwerp. Hierdie studie het ten doel gehad om die effektiwiteit en
veiligheid van lae dosis haloperidol in 'n Suid-Afrikaanse populasie van pasiënte
met EEP te evalueer.
Die studie is uitgevoer in twee fases:
Fase 1 was 'n oop, naturalistiese studie van 57 pasiënte met EEP wat
aanvanklik behandel is met 1mg haloperidol per dag vir 4 weke, waarna
geleidelike verhoging van dosisse toegelaat is, soos nodig. Diegene wat nie
bevredigende respons getoon het op haloperidol 10mg per dag nie, is
oorgeskakel na tioridasien. Ontoereikende respons teen 600mg/dag tioridasien is
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geïnterpreteer as 'n aanduiding van behandelingsweerstandigheid en
behandeling met klosapien is begin.
Die belangrikste bevinding van hierdie fase van die studie was dat die
meerderheid pasiënte gestabiliseer en in stand gehou kom word op baie lae
dosisse haloperidol (1.7 ± 1.0 mg/dag op 12 maande en 1.3 ±0.8 mg/dag op 24
maande).
Metings van ekstra-piramidale newe-effekte (EPNE) het nie beduidend
toegeneem oor die duur van die studie nie, behalwe in die geval van
tardiewe diskinese (TO), waar 'n beduidende aantal pasiënte (12.3%) TO
ontwikkel het binne 12 maande na aanvang van behandeling.
Fase 2 van die studie was 'n dubbelblinde, ewekansig gerandomiseerde studie
waarin behandeling met lae dosis haloperidol (2mg/dag) vergelyk is met
"standaard" dosis haloperidol (8mg/dag).
Veertig pasiënte is ingesluit in hierdie fase van die studie, 20 in elke
behandelingsarm. Die hoofbevinding was dat daar geen beduidende verskille in
respons op behandeling was tussen die twee groepe nie.
Daar was egter beduidende verskille in EPNE, waar die 8mg/dag groep
beduidend hoër vlakke van EPNE gehad het as die 2mg/dag groep.
Hierdie verskil in EPNE is aangedui deur 'n statisties beduidende verskil in
tellings op die Extrapyramidal Symptom Rating Scale (ESRS) en die Simpson-
Angus Rating Scale. Verder het pasiënte in die 8mg/dag groep beduidend hoër
dosisse antikolinerge medikasie benodig en ook hoër gemiddelde
prolaktienvlakke gehad teen die einde van studie.
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Hierdie studie dui dus daarop dat die meerderheid van pasiënte met EEP
suksesvol behandel en in stand gehou kan word met baie lae dosisse
haloperidol. Die studie wys ook daarop dat behandeling met lae dosisse net so
effektief is en beter verdra word as behandeling met "standaard" dosisse. Ten
spyte van die suksesvolle gebruik van lae dosisse medikasie het die studie egter
ook getoon dat daar "n baie hoër as verwagte insidensie was van TO, "n emstige
en potensieelonomkeerbare newe-effek van neuroleptiese behandeling.
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Introduction
The history of psychiatry has often been one of misunderstanding, prejudice and
neglect. Despite revolutionary discoveries in the field, particularly in
psychopharmacoloqy', many laymen, but also medical colleagues, view
psychiatry and psychiatrists with a mixture of fear and contempt.
In the medical fraternity, psychiatric illness is often seen as "not real", "self-
inflicted" or as having such a poor prognosis that treatment resources are better
applied elsewhere. This negative mindset reflects the prejudice of society as a
whole, where the primeval "fear of madness" seems to be as strong today as
ever.
Discrimination on the grounds of mental illness is reflected in the fact that
psychiatry remains the most poorly funded of medical specialties, with many
medical aid funds in South Africa either excluding or severely restricting benefits
for mental illness". This is also the case in the state sector, where funds available
for the treatment of mental illness are considerably less than those spent on
other specialties. In fact, most of the secondary hospitals in South Africa do not
even offer any psychiatric inpatient services, thereby increasing the load on the
already overburdened psychiatric hospitals where funds and services had been
severely cut in the drive for deinstitutionalization.
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The last decade of the twentieth century saw the publication of a number of
important papers that exposed the danger of disregarding mental health. One of
the most important of these papers was the Global Burden of Disease Studl.
This study was the first to employ the concept of "Disease adjusted life years"
(DALY's) and showed neuropsychiatric illness to be one of the principal causes
of disability and loss of productivity in the world. At the time of the study in the
mid-1990's, neuropsychiatric illness already accounted for more than 10% of
DALY's worldwide. Even in the developing world, this figure was more than 9%.
Of all the illnesses that psychiatrists treat, Schizophrenia is the most costly". It is
also an illness viewed by most as having a very poor prognosis, with inevitable
deterioration and permanent disability as the only likely outcome. Studies of first
episode psychosis (FEP) changed this perception for some, who came to realize
that, with appropriate and timeous intervention, patients could remain or once
more become active members of society.
However, the problem seems to be that many patients, who do well with initial
treatment, discontinue their medication due to side effects and then relapse into
psychosis again and again, with catastrophic consequences in terms of long-term
outcome. Poor compliance, mostly as a result of side effects, therefore is a major
contributing factor to the long-term impairment that patients with Schizophrenia
suffer. It is imperative that we as researchers and clinicians do our utmost to
ensure minimal side effects from the medication we prescribe, so that patients
will be encouraged to continue using their medication in order to ensure the
optimal outcome.
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Chapter 1
Schizophrenia - Etiology, Epidemiology, Symptoms and Signs
Although Schizophrenia has probably been around as long as humanity itself, it
has, until fairly recently, been a disorder veiled in myth and prejudice.
Emil Kraepelin (1856 - 1926) and Eugene Bleuler(1857 - 1939) were the two
most important historical figures in the medicalization of this disorder. Benedict
Morel who first used the term demense precoce, but it came to be associated
with our current concept of Schizophrenia as a result of Kreapelin's description of
what he termed dementia praecox.
Bleuier introduced the term Schizophrenia to describe what he saw as a schism
between emotion, behaviour and thinklnq",
Although the interpretation of the concept of Schizophrenia and the diagnostic
boundaries thereof varied widely over the years, the introduction of the DSM-III in
the early 1980's helped to standardize the diagnostic criteria for this disorder.
Today, clinicians across the world have access to a standard set of reliable,
tested and proven criteria in the form of the DSM-IV6. This has helped not only to
improve diagnostic accuracy, but has also advanced research into and,
consequently, treatment of Schizophrenia.
11
Stellenbosch University http://scholar.sun.ac.za
The DSM-IV criteria for Schizophrenia are as follows:
A. Characteristic Symptoms: Two or more of the following, each present for a significant portion of time
during a 1-month period (or less if successfully treated):
1. Delusions
2. Hallucinations
3. Disorganized speech
4. Grossly disorganized or catatonic behaviour
5. Negative symptoms, i.e. affective flattening, alogia, or avoIition.
Note: Only one criterion A symptom is required if delusions are bizarre or hallucinations consist of
a voice keeping up a running commentary on the person's behaviour or thoughts, or two or more
voices conversing with each other.
B. Social/Occupational Dysfunction: For a significant portion of the time since the onset of the
disturbance, one or more major areas of functioning, such as work, interpersonal relations or self-care,
are markedly below the level achieved prior to the onset.
C. Duration: Continuous signs of the disturbance persist for at least six months. This six-month period
must include at least one month of symptoms that meet criterion A (i.e. active phase symptoms) and
may include periods of prodromal or residual symptoms. During these prodromal or residual periods,
the signs of the disturbance may be manifested by only negative symptoms or two or more symptoms
listed in criterion A in an attentuated form. (E.g. odd beliefs, unusual perceptual experiences.)
D. Schizoaffective and Mood Disorder Exclusion: Schizoaffective disorder and mood disorder with
psychotic features have been ruled out because either: 1) no major depressive, manic or mixed
episodes have occurred concurrently with the active phase symptoms or 2) if mood episodes have
occurred during active phase symptoms their total duration has been brief relative to the duration of the
active and residual periods.
E. Substance! General medical condition exclusion: This disturbance is not due to the direct
physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition.
F. Relationship to a pervasive developmental disorder. If there is a history of autistic disorder or
another pervasive developmental disorder the additional diagnosis of Schizophrenia is only made if
prominent delusions or hallucinations are also present for at least a month (or less if successfully
treated.)
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Epidemiology
Schizophrenia has a prevalence rate of approximately 1% in the general
population". Despite its fairly low prevalence however, its chronic, often
debilitating course leads it to consume a considerably larger proportion of health
expenditure than ifs prevalence would suggest4;7. In fact, Schizophrenia is not
only the most expensive disorder that psychiatrists treat in terms of direct cost,
but has also - as discussed ear1ier- been shown to be one of the leading causes
of disability in the world",
Although Schizophrenia is equally prevalent in the sexes, its mean age of onset
in men, at between 15 - 25 years of age, is about a decade ear1ierthan in
women. Schizophrenia occurs all over the world and in all population groups,
however it is not equally distributed throughout the world, with higher prevalence
in some areas. In industrialized societies for example, Schizophrenia is more
common in low socio-economic groups and also in immigrant populations".
Etiology
Despite many years of research, the cause(s) of Schizophrenia continues to
elude us. From the end of the nineteenth century, up to the middle of the
twentieth century, psychoanalytic theory was dominant in psychiatry. The
concept of an ego defect and ego disintegration with a return to a time before the
ego had been established was put forward as the cause of psychosis.
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Regression in response to conflict and frustration was central to this theory, and
was elaborated on by many authors in this field9.
Towards the second half of the twentieth century however, there was a major
change in thinking about the cause of psychiatric illness in general and
Schizophrenia in particular. With technological advances in brain imaging and
neuropathology, evidence slowly mounted for a biological cause for
Schizophrenia. The strongest evidence for the biological underpinnings of the
disorder however came with the discovery of chlorpromazine and subsequent
studies that proved the efficacy of antipsychotic medications in the treatment of
Schizophrenia 10.
Evidence from a variety of sources, including neuro-imaging and neuropathology,
suggest abnormalities of brain structure in patients with Schizophrenia 11-13:
a) Neuro-imaging studies show patients with Schizophrenia to have larger lateral
ventricles 14 and, to a lesser extent, third and fourth ventricles as well as the loss
of the normal asymmetry seen in the human brain 15. These abnormalities seem
to be present at the onset of symptoms and remain static12;13, although some
authors 16 suggest that they may be progressive.
b) Neuropathological findings have confirmed these neuro-imaging findings, and
also report reduced cortical volume and neuronal density". loss of grey matter in
selected areas such as the hippocampus and amygdala, reduction in number
and abnormal arrangement of neurons 18 and lack of gliosis 19. This lack of gliosis
supports the idea that the insult occurs early in the development of the foetal
14
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brain, as gliosis will only occur after the second trimester of pregnancy. Also,
neuropathological findings in post-mortem examination of the brains of patients
with Schizophrenia are suggestive of abnormal neural migration in the
developing brain18. Taken together, these findings support the widely held theory
that Schizophrenia is a neurodevelopmental disorder".
Further support for the neurodevelopmental theory of Schizophrenia comes from
evidence of increased risk with obstetric complications21;22, maternal
rnalnutrttlorr" and influenza during preqnarcy". All of these risk factors may be
expressed in a "final common pathway" that leads to the development of
Schizophrenia.
On the synaptic level, the dopamine theory has long been the prevaling theory of
the etiology of Schlzophrenta". In it's most basic form, this theory states that
excess dopamine causes psychosis. Most authors realize that this is a gross
oversimplification of the psychobiology of the disorder, however, some
dysregulation of dopaminergic neurotransmission is clearly involved (see full
discussion of dopamine receptor later).
15
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The Symptom Complex of Schizophrenia
Delusions and hallucinations have long been regarded as the hallmark of
Schizophrenia and also the focus of its treatment. This came to be despite the
fact that the so-called "first-rank" symptoms of Schizophrenia are neither
necessary nor sufficient for the diagnosis of the disorder. To this day, many
clinicians still see the presence of hallucinations and delusions as the principal
diagnostic features. It is therefore important to reiterate the fact that there is not a
single symptom or sign that is pathognomonic for Schizophrenia, as they may
also occur in other psychiatric or neurological disorders",
It was Timothy Crow who proposed the concept of type I and Type II
Schizophreniaê", thereby emphasizing the presence (or absence) of the "positive"
(hallucinations, delusions, positive thought disorder) and "negative" (affective
flattening, alogia, avolition-apathy, social withdrawal, attention problems)
symptoms of Schizophrenia.
More recently, factor analysis of the Positive and Negative Syndrome Scale
(PANSS)27 has revealed 5 symptom clusters in Schizophrenia, namely: positive
symptoms, negative symptoms, cognitive symptoms, mood symptoms and
aggression/hostility28. This is of great importance, as each of these symptom-
clusters may impact on the eventual outcome and deserve treatment in it's own
right. Each should therefore be evaluated, rated and followed closely. Clinicians
should be aware of the fact that medication that treats the positive symptoms of
the disorder may not be effective in treating other domains of the illness and may
16
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make some of the other symptoms worse." This fact makes an intimate
knowledge and dose follow-up of each target symptom cluster imperative.
Let us consider each of the symptom clusters:
Positive symptoms
Hallucinations, Delusions, Positive Thought Disorder.
These are the best-known symptoms of Schizophrenia. They are however
not specific to Schizophrenia and may be present in a variety of other
psychotic disorders, such as psychotic mood disorders, substance induced
psychotic disorders and others. Although they are therefore classic
symptoms, they are neither necessary nor sufficient for a diagnosis of
Schizophrenia. This does not detract from the fact that they cause great
distress to both patients and carers and should be a major focus of treatment.
In fact, recent studies suggest that our aim should be to eradicate these
symptoms altogether, as symptoms of psychosis, however mild, may reflect
an ongoing "toxic" effect on the brain with negative implications for long-term
outcome":".
17
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Negative Symptoms
These symptoms are also known as deficit symptoms and describe a loss
of normal function. Andreasen'" describes the following negative
symptoms:
1. Affective flattening (such as paucity of expressive
gestures, poor eye contact, affective non-responsivity, etc.)
2. Alogia (poverty of speech, thought blocking, increased
response latency, etc.)
3. Avolition- Apathy (poor grooming and hygiene, physical
anergia, impersistence in school/work)
4. Anhedonia- Asociality (reduction in recreational
interests, reduced sexual interest, fewer interpersonal contacts,
relationships. )
6. Attention (social inattentiveness, inattentiveness during
testing)
These symptoms are of importance, and clinicians should distinguish between
primary and secondary negative symptoms", Primary negative symptoms are
those symptoms that are seen as "core" features of the disorder, whereas
secondary negative symptoms may be the result of side effects of medication,
secondary to positive symptoms, secondary to depressive symptoms or due to
lack of environmental stimulation. Secondary negative symptoms are therefore
more likely to respond to appropriate treatment or adjustments in medication.
18
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Mood Symptoms
Despite the fact that mood disorders and Schizophrenia are traditionally
conceptualized as separate disorders, mood symptoms are common in
Schizophrenia'", Whereas they were previously thought to be uncommon in the
acute phase of the illness, it is now recognized that depressive symptoms are a
key feature of the acute psychotic episode, and that the majority of these
symptoms resolve with antipsychotic treatment", From the available data, it
would appear that mood symptoms in the acute phase of Schizophrenia might be
associated with a favourable outcome", while persistent depressive symptoms
appear to be negative prognostic indicators37-39.
Cognitive Symptoms
Problems in cognitive functioning in Schizophrenia have been described since
the time of Kraepelin. In recent years, more detailed research has shown that the
cognitive dysfunction in Schizophrenia, although wide spread, seems to involve
the areas of memory, attention and executive functions in particular". More
importantly, these deficits seem to be the principal indicators of poor outcome in
terms of skills learning and work rehabllltatlon". These deficits are not
irreversible, but can be treated.
19
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Aggression/Hostility
A patient experiencing a psychotic episode may become hostile, aggressive and
violent. This behaviour is, however, not unique to psychosis or even to
psychiatric disorders, although a diagnosis of Schizophrenia increases the risk
thereof. Psychotic patients may act on the instructions of command-type
hallucinations, may respond to delusions or may act out in disorganized or
excited states. The role of the clinician is to be aware of the risk, to assess and
treat it appropriately, always with the patient's best interest at heart.
Outcome
Early studies on the long-term outcome of persons suffering with Schizophrenia
started with that of Bleuier in 196642. We now know from this study and
others43:44 that approximately 20% of patients recover, with a further 25% who
make signifcant improvements. This leaves at least fifty percent of patients with
a chronic, unremitting course of illness, requiring care and follow-up.
20
Stellenbosch University http://scholar.sun.ac.za
Chapter 2
Why should we be paying special attention to the patient with a first
episode of psychosis?
In the 1980's, a number of researchers began to investigate the early phases of
psychotic illness. Their findings have lead to the realization that this
subpopulation of patients may offer unique opportunities in the treatment of
Schizophrenia45-5o•
There are now a number of well-established first-episode programmes around
the world. In South Africa however, this area has been poorly studied and there
are no known publications that refer specifically to a South African population of
patients with first-episode psychosis. There are numerous reasons why a specific
and special focus on first-episode psychosis is important:
a) Kraepelinian doctrine holds that dementia praecox is a deteriorating illness
with poor long-term outcome. Bleuer, on the other hand, suggested that patients
deteriorate early in the course of illness but then reach a plateau of relative
stability in psychopatholoqy".
More recent work has supported Bleuler's notion of early deterioration and
stabtllzatlon'", eventually leading to the introduction of the concept of the "critical
period" by Birchwood et aI45;52. Birchwood52 suggests "the early phase of
psychosis is a critical period for intervention, offering major opportunities for
21
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secondary prevention of the impairments and disabilities that accompany
psychosis" (531).
In this theory deterioration in function occurs in the prodrome, as well as in the
early phases of the illness, but stabilizes after 2-5 years (the so-called plateau'"),
There may even be some improvement in functioning in certain patients later in
their illness. Intervention should therefore be aimed at getting the patient to
effective treatment before they have progressed too far down the slope of
deterioration, preferrably within a few weeks or months after the onset of illness,
if not before.
b) It is a well-established fact that patients with a first episode of psychosis show
better response to treatment than patients with chronic illness 54-57. In published
trials of short-term treatment of first-episode patients that lasted several weeks,
response rates were around 60%58-60. Even though this was a high early
response rate, it has been pointed out that this may be an underestimation of the
responsiveness of first-episode patients to treatment, as the time to response
may be considerably longer. In the study of first-episode psychosis from the New
York Group, it was found that a cumulative response rate of more than 80% was
achieved after one year of treatment". First-episode patients also required lower
doses of medication than patients with chronic iIIness61;62 and were more
vulnerable to side-effects'".
c) Another, related factor suggesting intervention as early as possible in the
"critical period", is the effect of the duration of untreated psychosis (DUP).
22
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The period of untreated psychosis immediately before the first contact is a highly
traumatic time for both patient and family and there are often many obstacles
preventing the patient from reaching appropriate help. From a psychological point
of view, patients who have an insidious onset of symptoms with a lenghty
prodromal phase may be dysfunctional over a long period of time in many
spheres of life. This is very likely to lead to vocational and educational
underachievement, but may also cause social isolation and disruption of
interpersonal relationships with reluctance on the behalf of others to help. Fear,
bewilderment, denial and a combative coping style coupled with prejudice on
behalf of patients, carers and helping professionals are all features of this phase
that work against appropriate diagnostic and treatment interventions64;65.
There have also been claims of a relationship between DUP and outcome on a
biological basis. Wyatt was the first to suggest that untreated psychosis may
have a "biologically toxic" effect on the brain, with obvious implications for
outcome and treatment resistance31;66;67. This theory has been supported by a
number of studies which found a relation between the DUP and outcome on a
variety of measures46;48;68-71. Although others have questioned these findings72;73,
the available data seems to suggest that a longer DUP may either be the cause
or the signal of a deteriorating course".
d) Mood symptoms, and in particular depression, are known to be more common
in first episode patients than in patients with chronic illness, with resulting
increased risk of suicide34;35. Patients with first-episode psychosis are exposed to
many traumatizing events that doctors often overlook:
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1) The effects of the psychosis itself, with potentially frightening delusions
and hallucinations.
2) The first contact with mental health services, which is very often not a
positive or helpful one and which may lead to severe distress"
3) The process of hospitalization (which is often involuntary),
4) The unpleasant experience of so-called "intensive care units" filled with
many psychotic, often agitated and sometimes-violent fellow-patients,
5) Medication (often administered against the patient's wishes) and it's
side effects.
These experiences are so unpleasant that patients may develop symptoms of
post-traumatic stress disorder'S.
e) From the researcher's point of view, the first episode presents that rare
opportunity to evaluate the natural course of the illness, from its earliest phases.
Furthermore, patients can be evaluated without the confounding factors of
medication and it's side effects. This may tell us more about the many features of
Schizophrenia, including the cognitive dysfunctions, the brain abnormalities and
the presence or absence of neurological deficits before medication is initiated. A
number of findings on the unique biological features of first-episode psychosis
have been published and it was found that at least some of the known biological
changes seen in patients with Schizophrenia might already be present early in
the course of the illness:
A variety of computerized tomography (CT) and magnetic resonance imaging
(MRI) studies have shown that patients with first-episode psychosis have
24
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enlarged lateral ventricles (ventricle-brain ratio f5-77, third ventricles 12, reduced
brain volume and a reduction in the normal hemispheric asymmetry of the brain
when compared to normal controls. Although this was seen by some as
supporting a neurodevelopmental disorder", it was also noted to be less
prevalent and less severe than in patients with chronic Schizophrenia 11.
Lieberman et al78 found that patients with a first-episode of psychosis and
questionable or definite brain pathomorphologic features took significantly longer
to recover and also achieved poorer levels of remission. In this same study,
abnormal basal growth hormone levels were also found to be an indicator of
longer time to remission.
In conclusion it can be said that there is now ample evidence that early
intervention in Schizophrenia may prevent, and in some cases even reverse,
deterioration in functioning. Early intervention significantly improves the likelihood
of remission in symptoms and return to functionality. A very specialized
programme of treatment is needed however, if we hope to make the kind of
interventions that will allow maximum effect and compliance with treatment with
minimum side effects.
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Chapter 3
Current treatment strategies for Schizophrenia and First-Episode
Psychosis
The treatment of Schizophrenia is a complex endeavour, requiring skilled
clinicians with a thorough knowledge of biological, psychosocial and
environmental intervention strategies. Whereas custodial care was the model for
the treatment of severe psychiatric disorders during most of the twentieth
century, the last two decades of the previous millenium saw a new emphasis on
cost-effectiveness and deinstitutionalization.
Although there have been marked improvements in many areas of care,
psychopharmacological intervention remains the cornerstone of the treatment of
Schizophrenia 10. Whereas patients were treated with high doses of
antipsychotics in the past, recent years have seen a greater realization of the
heterogeneity in response to medication, both in terms of effect and side effects.
Also, many researchers have published data to show that large doses of
medication afford no additional benefits and will not induce more rapid
response" ;79-83. However, the 1970's and 1980's saw a continuous increase in
the use of high doses of high potency antisychotics, despite the lack of research
data to support this practice".
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Despite the fact that more clinicians are becoming aware of first-episode patients
as a unique group (see Chapter 2), there are still no clear guidelines on how they
should be treated. Tlis is reflected both in the literature and the
psychopharmacological treatment trials:
Guidelines and books
The more recent past has seen the publication of a number of guidelines to
advise clinicians on the correct treatment of Schizophrenia in generaI85;86,but
also for the treatment of first-episodes of psychosis87-89.
As an example, the PORT treatment recornrnendations'" suggest doses of
antipsychotic medication for Schizophrenia of between 300 - 1000
chlorpromazine (CPZ) equivalents. For first-episode psychosis, their
recommendation is the following:
"Persons experiencing their first acute symptom episode should be treated with
an antipsychotic medication other than clozapine, but dosages should remain in
the lower end of the range mentioned ... " (Page 2). In their table of treatment
options, the dose range suggested for haloperidol is 6 - 20mg during the acute
phase and 6 - 12 mg during the maintenance phase. Baldessarini also
suggested doses of between 10- 12 mg for acute treatment, while 6 - 12 mg is
suggested for maintenance therapl9.
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At the lower extreme, Aitchison et al87 suggests that "..an appropriate treatment
protocol for first-episode psychosis would be to initiate antipsychotic treatment at
a very low dose (eg 2mg haloperidol or 100mg chlorpromazine equivalents)"
(page 51).
Acute treatment studies
In the first-episode study of risperidone and haloperidol by Emsley et a1.90, 183
patients with a first episode of psychosis were treated with either risperidone or
haloperidol in a double blind, flexible-dose design over a six week period. In this
study, it was found that low doses of both medications were effective and better
tolerated than high doses. In this study, the mean daily dose of haloperidol was
5.6mg per day. It also found that doses of 6mg or less were effective and better
tolerated than doses greater than 6mg per day.
Recommendations of even lower doses came from the Toronto Group, who, on
the basis of their positron emission tomography (PET) findings, suggested doses
as low as 2 - 6mg per day for the treatment of first-episode psychosls'", There
are, however very few clinical studies to back up this recommendanon'T", while
there are also studies to suggest that these doses may in fact, be too low82;91;92
In the study by the Scottish Schizophrenia group, patients were randomized to
treatment with either pimozide or flupenthixol for 5 weeks of double-blind
treatment. The doses in this study started at 10mg and went up to 40mg per day
in the case of pimozide and 50mg per day in the case of flupenthixol. Patients
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were evaluated with the Research Diagnostic Criteria (RDC)93and Feighner
crlteria'". Sixty-three percent of patients were classified as responders to
medication. Non-responders were more likely to be male, have neurological
signs, cognitive deficits and negative symptoms. The mean daily dose of
medication was 18.8 mg of pimozide and 20mg flupenthixol per day. What was of
significance here was that most patients in this study required anti-parkinsonian
medication for EPS and that plasma neuroleptic levels showed compliance to be
extremely poor.
In an open treatment protocol of first-episode psychosis patients with DSM-IV
defined Schizophrenia, Kopala et al58used risperidone as treatment, starting on
1mg twice daily and increasing doses slowly. The mean daily dose for
risperidone in this study was 4.7(±1.5) mg per day and they reported a 59%
response.
What was to become probably the best known and most widely-quoted first-
episode study in the world was conducted by Lieberman et aI47;55;59;78;95-102in
New York. In this large, open trial at Hillside Hospital, patients were included if
they had definite or probable Schizophrenia according to RDC, were aged
between 16- 40 and had no serious medical illness.
Patients were treated with sequential trials of fluphenazine (20mg for 6 weeks,
then 40 mg for 4 weeks), haloperidol (20mg for 6 weeks, then 40mg for 4 weeks),
molindone (up to 300mg per day) and clozapine (up to 900mg per day). It seems,
therefore, not surprising that 62% of patients developed extra-pyramidal side
effects 103!
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A most interesting study of treatment of first-episode psychosis is that by Zhang-
Wong et a162• In this study, 36 patients were treated with haloperidol according to
the following protocol: In the first week, all patients received haloperidol 2mg per
day. The dose of haloperidol was then increased weekly until either a) PANSS
had improved by 15% or b) side-effects developed. Drug doses were
standardized to 5mg at day 8, 10mg at day 15, and 20mg at day 22. Doses were
frozen for the remainder of the study period once the optimal dose was reached.
The median optimal daily dose of haloperidol in this group was 5mg per day.
However, 42% of subjects in this group achieved optimal response at haloperidol
2mg per day, whereas only 8% of patients responded at 20mg per day. The
authors found that EPS were rare at the low doses and they remarked that, had
the trial period at each level been extended beyond one week, more patients
might have responded.
Studies of maintenance treatment
In the Northwick Park Study1°4,first-episode patients were not treated uniformly
during admission to hospital. However, after discharge from hospital, 120
patients formed part of a placebo-controlled, randomized trial of maintenance
neuroleptic medication. Minimum doses of medication were set, but no upper
limits. In the case of haloperidol, this minimum dose was set at 3mg per day, but,
by the end of the study, the mean daily dose of haloperidol was 11.75mg per
day. The study had a high relapse rate of 46% of patients on active treatment
and 62% of patients on placebo within two years of discharge form hospital.
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Better outcome was reported by Kane et al54, who found no relapses after 1 year
in the group of first-episode psychosis patients treated with fluphenazine (either
oral 5-20mg per day or depot 12.5 - 50mg bi-weekly). This was considerably
better than the 7/17 that relapsed on placebo.
A small group of 15 patients from the Scottish First Episode Schizophrenia
Study, who were stable on treatment for one year after their initial episode, were
randomized into treatment with either flupenthixol or pimozide as active
treatment, or ptacebo?". This treatment regime was followed for a further 12
months. The mean daily dose at the end was 18.8mg pimozide and 20mg
flupenthixol. Of the 8 patients on active treatment, none relapsed, whereas 4 of
the 7 patients on placebo relapsed and were readmitted.
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Chapter 4
The role of dopamine and serotonin in psychosis and its treatment
Before the age of modern psychopharmacology, institutionalization was often the
only treatment option available for patients with chronic mental illness and, by the
middle of this century, reached it's zenith when almost 560 000 patients were
residents of psychiatric institutions in the United States alone106. The
serendipitous discovery of chlorpromazine, however signaled the start of a
revolution in mental health care1. More and more attention was focused on
medical and specifically pharmacological intervention in the treatment of
psychiatric disorders.
Although clinicians had no idea as to the molecular mechanisms underlying the
antipsychotic effects of chlorpromazine at its introduction in the mid 1950's, it
became clear during the next twenty years that the major effect was mediated
through the ability of the medication to block dopamine receptors in the brain. At
least 5 subtypes of dopamine receptor have since been identified107. They are
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divided into two broad families: the Di-like (including 01 and 05 subtypes) and
the 02-1ike(including O2,03 and 04) receptor subtypes.
Although there is good evidence for the O2receptor subtype's involvement in
Schizophrenia, the clinical role of the other subtypes remains uncertain.
The classic observation by Seeman and others 108that the potency of
antipsychotic medications correlated with their affinity for dopamine 02 receptors
in the basal ganglia remains one of the principal components of the dopamine
theory of psychosis. Whatever else they may do, all antipsychotic medications
have this in common: they block 02 receptors 109.In fact, no medication that did
not block these receptors has ever been proven as a successful antipsychotic
treatment.
Four major pathways have been identified for dopaminergic neurotransmission in
the human brain11o:
1. Meso/imbic pathway. Cell bodies arise in the ventral tegmental area of the
brainstem and project to limbic areas of the brain, sum as the nucleus
accumbens. It is thought that it is dopaminergic dysregulation in this pathway
that is responsible for the so-called positive symptoms of Schizophrenia.
2. Mesocorlical pathway. Cell bodies arise in the ventral tegmental area of the
brainstem and project to the cerebral cortex. Oysregulation in this pathway is
thought to be implicated in the negative and cognitive features of
Schizophrenia.
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3. Nigrostriatal pathway. Cell bodies project from the substantia nigra in the
brainstem to the striatum. Dysregulation in this pathway is implicated in
movement disorders such as Parkinson's disease, chorea and tics.
4. Tuberoinfundibular pathway. Cell bodies project from the hypothalamus to
the anterior pituitary. These neurons normally inhibit prolactin secretion.
While antipsychotic medications reduce positive symptoms of Schizophrenia
through its effects on the mesolimbic dopaminergic pathway, the first-generation
antipsychotic medications seem unable to discriminate between different areas of
the brain in terms of dopamine blockade. By blocking D2 receptors in the other
three dopaminergic pathways in the brain, they cause the well-known side effects
of this class of medication:
1. Nigrostriatal pathway - pseudo-parkinsonism, akathisia, dystonia, tardive
dyskinesia.
2. Mesocorlical pathway - cognitive dulling, secondary negative symptoms,
secondary mood symptoms.
3. Tuberoinfundibular pathway - hyper-prolactinaemia
Recently, much attention has been focused on the role of the serotonergic
system in the effects of antipsychotic medications. It has been suggested that
manipulation of the serotonergic system and it's interaction with the
dopaminergic system can reduce EPS and even enhance antipsychotic
efficacy'!' ;112.
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Serotonergic projections from the dorsal raphe project to the substantia nigra,
where they have an inhibitory effect on dopaminergic neurons 113.This inhibition
is mediated via the 5HT2A receptor, which is located on the somatodendritic
surface of the dopaminergic neuron. Similar projections via the median forebrain
bundle connect the raphe nuclei to the frontal cortex. Here, too, serotonergic
stimulation inhibits the release of endogenous dopamine.
Because of this mechanism, particular emphasis has been placed on the
serotonergic 5HT2Areceptor. It has been proposed that blockade of this receptor,
in addition to the blockade of the O2receptor, may explain the "atypicality" of the
second- generation antipsychotics, at least to some extent!". Firstly, it seems
that blockade of the 5HT2A receptor widens the therapeutic "window" between
antipsychotic effect (usually around 70% O2occupancy) and the threshold for the
development of EPS (around 80% O2occupancy)!", Secondly, it has been
suggested that serotonergic receptor blockade may be the mechanism by which
the second-generation antipsychotics treat the negative symptoms of
Schizophrenia 112.This is based on animal studies that found antagonism of the
5HT2A receptor to increase dopamine in the limbic system 116.The idea is
therefore that, depending on which dopamine pathway we care to look at,
different results of 5HT2A blockade will be observed:
1. In the nigrostriatal pathway, blockade of 5HT2Areverses the inhibitory effect of
serotonin on dopamine, thereby promoting dopamine release into the
synaptic cleft and overcoming EPS. As there are relatively higher numbers of
O2receptors in this area when compared to 5HT2A receptors, this effect is
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only partially successful and dose dependent, i.e. for some of the second-
generation antipsychotics, high doses of medication will overcome the
protective effect of 5HT2A blockade and EPS will appear.
2. In the mesocortical pathway, the balance of receptors favours 5HT2Aover O2.
Therefore, blockade of the 5HT2A receptors may have a more profound pro-
dopamine effect in the frontal areas than in the striatum. This may be involved
in the suggested better effect on cognition and negative symptoms with
second-generation antipsychotic medications. Studies with ritanserin 117;118
support this theory: in a study with ritanserin, which is a blocker of both 5HT2A
and 5HT2C,it was found to be effective in the treatment of negative
symptoms. A second, non-dopaminergic mechanism may also be involved
here: serotonergic projections have a direct inhibitory effect on prefrontal
neurons that is not dependent on dopamine. Blockade of 5HT2A receptors
may therefore lift this inhibitory effect as well.
3. In the tubero-infundibular pathway, dopamine inhibits prolactin secretion,
whereas serotonergic stimulation of the 5HT2Areceptor promotes prolactin
secretion. With the first-generation antipsychotic medications, the blockade of
02 receptors leads to hyperprolactineamia. With the second- generation
anti psychotics, though, there are not only reduced O2blocking properties, but
also the mitigating effect of 5HT2A blockade and therefore less promotion of
prolactin secretion.
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4. In the mesolimbic pathway, the atypical antipsychotic achieves enough ~
receptor antagonism that is not reversed by 5HT2A antagonism to have a
profound and effective antipsychotic effect.
Probably the best clinical example of this dopamine-serotonin interaction is seen
in the clinical effects of risperidone, one of the second-generation antipsychotic
medications. Risperidone has been shown to be equipotent to haloperidol at the
O2 receptor. However, at doses below 6mg per day, risperidone seems much
less likely to cause EPS than haloperidol. In doses beyond 6-8mg per day, the
risk of EPS between risperidone and haloperidol becomes lndlstingulshablell".
The reason for this seems to be that, up to a dose of 6mg per day, risperidone
demonstrates higher 5HT2A occupancy than O2 occupancy, and the serotonergic
disinhibition is therefore able to prevenUovercome the risk of EPS. As we move
beyond this threshold dose however, the O2 occupancy becomes higher than
5HT2A occupancy, resulting in the appearance of EPS.
It has to be kept in mind though, that many different subtypes of the serotonin
receptors have been and continue to be cloned and may therefore have a role in
"atypicality". For example, some authors suggest that clozapine's high affinity for
the 5HT6 receptor may be the key to its unique properties as an antipsychotic
medication 120. Also, with this theory in mind, one would expect medications that
increase serotonin levels in the brain to worsen the side effects of antipsychotic
medications. This is partly true: some studies have found selective serotonin
reuptake inhibitors (SSRI's) to cause EPS, akathisia, tremor and dystonial".
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However, others have found significant improvements in negative symptoms with
SSRI's. Some authors suggest that this may in fact be a result of the effect of
SSRI's on mood symptoms that are masking as negative symptoms, however the
specific mechanism remains unclear.
Although the dopamine-serotonin interaction therefore seems to be important,
the classic interplay as seen with risperidone is not seen with all the second-
generation antipsychotic medications. Other second-generation antipsychotic
medications are as effective as risperidone, but show lower affinity for the 02
receptor, with clozapine and quetiapine the two medications at the extreme of the
spectrum. Both of these medications cause virtually no EPS at any dose,
primarily because of the fact that the "threshhold" for EPS is not reached. In fact,
clozapine's occupancy of O2 receptors has been reported in a number of studies
to vary from 20% - 67% 121. Indeed, the existence of a "glass ceiling" has been
suggested to describe the relationship between clozapine dose and 02
occupancv!",
The traditional concept of potency in terms of affinity for O2 receptors seemed to
be lost therefore, with the introdudion of the second-generation antipsychotics.
Although clozapine has been proven to be a highly effective antipsychotic
medication, it's occupation of O2 receptors in the striatum was found to be
considerably less that the 70% or more thought to be needed for antipsychotic
effect115;121. This has lead to the idea that other mechanisms may be involved in
the antipsychotic effect of what has become known as the multi-receptor
antagonists.
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One such putative mechanism is via the blocking of the dopamine 04 receptor
sUbtype122. This receptor subtype was suggested as a candidate on the basis of
clozapine's very high affinity for it and a report of higher levels of this receptor in
the brains of patients with Schizophrenia 123. I-Iowever, a study with the selective
04 antagonist L745,870 proved to be unsuccessful as a treatment for acutely
psychotic patients 124.
More recent findings regarding the pharmacokinetics of antipsychotic
medications have introduced a completely new concept to the issue of atypicality,
this being the notion of "loose" and "tlqht" binding at the level of the receptor. To
understand this, we need to consider carefully the pharmacokinetics at the
receptor level. Strange et al125 points out that the level of dopamine at the
synapse is not fixed, and may change over time. These changes in levels of
dopamine may affect the effects of antipsychotic medications by competing for
dopamine receptors. Medications with a high dissociation constant (Kd) will bind
to the dopaminergic receptor more loosely than medication with a low Kd.
Examples of medications with high Kd are clozapine and quetiapine. Examples of
medications with low Kd are haloperidol and chlorpromazine. The latter two will
therefore not dissociate rapidly from the receptor. The rapid dissociation of the
medications with a high Kd may explain at least some of the "atypicality" of these
compounds and provide additional protection against the development of EPS.
What this may also imply is that, contrary to what we believed up to now, the
second-generation antipsychotic medications (in particular clozapine and
quetiapine), do in fact bind with the 02 receptors to the same extent as do the
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first-generation antipsychotics, but this binding is only transient. This was shown
to be the case with quetiapine in a PET-study by Kapur et a1126,which showed
that the O2 occupancy by this medication declined rapidly from 58% three hours
post dose to only 20% at 12 hours post dose. This may call into question many of
the O2 occupancy studies where patients received medication and the occupancy
was measured approximately 12 hours later.
Kapur and Seeman 127 recently suggested that the multireceptor hypotheses may,
in fact, be wrong and that the basis for atypicality may lie in the fast dissociation
of certain compounds from the 02 receptor. According to these authors, "the
blockade of other receptors (other than O2) is neither necessary nor sufficient."
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Chapter 5
Extrapyramidal side-effects
Although extrapyramidal symptoms are often mentioned in research protocols
and textbooks of psychiatry, they seldom receive the attention it deserves in
clinical settings. The side-effects of dystonia, parkinsonism, akathisia and tardive
dyskinesia seem to interest clinicians only when overwhelmingly obvious, and
sometimes not even then.
There are many reasons why the recognition and treatment of EPS are important
in psychiatry, such as their disfiguring, stigmatizing nature and the fact that they
may, at times, be life-threatening 128;129. But it also has an important role in the
ongoing problem of non-compliance.
Poor compliance remains one of the largest problems in psychiatry, with some
studies showing levels of non-compliance of up to 74% within two years after
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discharge from hospital13o. At least two important studies have shown that the
side effects of medication are either a major reason or the principal reason for
medication non-oompliance amongst patients taking antipsychotic
medications131;132. What is of even greater concern though, is the fact that
clinicians are so poorly skilled at detecting EPS. Hoge et al131 showed that,
whereas 35% of patients rated side effects as the principal reason for their non-
compliance with treatment, only 7% of the clinicians treating them did so. Also, in
the study by Weiden et a113o, it was shown that clinicians fail to recognize side
effects in the majority of patients, recognizing akathisia in only 26% of cases and
tardive dyskinesia in only 10% of cases!". This has not only become a major
clinical dilemma, but has, in many parts of the world, also become a medico-legal
issue, as patients and families become more aware of the rights of the patient
and the responsibilties of the physician.
For those clinicians who work in the developing world and who have to rely on
medications such as haloperidol for the treatment of psychotic illnesses 133, it is
important to know that medication-induced parkinsonism is more likely to occur
with the high potency medications (such as haloperidol), than with low potency
medications. Also, it should be remembered that, whereas tremor is a common
sign of Parkinson's disease, the medication-induced parkinsonism of
antipsychotic medication seldom has tremor as a prominent feature. Rigidity and
bradykinesia are more common signs, often missed by psychiatrists who believe
them to be features of negative symptoms.
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Akathisia is probably the most distressing of the EPS, with an incidence of
approximately 25% in most major studies 134. It is first experienced as a subjective
restlessness, before objective signs become evident. It is often confused with
psychotic agitation or anxiety and may result in even larger doses of
antipsychotic medication being administered, thereby worsening an already
distressing situation.
Acute dystonic reactions are not only painful and distressing to the patient, but
may also be dangerous - dystonia may cause severe respiratory impairment as
a result of laryngeal addudor spasm as well as dysphagia as a consequence of
pharyngeal dystonia 135. Acute dystonia seems to occur more commonly with the
use of high potency antipsychotics, and young, first-episode patients who are
medication-naïve seem to be at particular risk of developing this problem 136.
Although EPS are known to occur in never-medicated populations 137:138, they are
certainly less prevalent and more subtle than in patients treated with
antipsychotic rnedlcation'I". First-episode patients are more sensitive to the side
effects of medication and more likely to develop acute EPS63.
Dyskinetic movement disorders are also known to occur in patients who have
never been exposed to antipsychotic medication 139:140, but are considerably more
prevalent in patients treated with antipsychotic medlcationl". In a large study,
Woemer et al142 reported prevalence rates in patients treated with antipsychotic
medications to be around 23%, whereas prevalence rates of tardive dyskinesia
(TD) in patients never treated with antipsychotics were below 3%.
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In clinical settings, tardive dyskinesia remains very much an underdiagnosed
and, therefore undertreated disorder':". Incidence studies report figures of
approximately 5% per year of treatment with antipsychotics 144.A similar figure of
4.8% has been reported for the first year in a first-episode psychosis group, with
figures increasing to about 16% after four years145.In this study from Hillside
Hospital, both dose of medication and poor treatment response were significant
predictors of time to onset of TO. In terms of the dose of medication, each
100mg-chlorpromazine equivalents increased the hazard of developing TO by
5%. Other authors have also suggested dose as a risk factor for the development
of T0144.
Other risk factors for TO that have been reported are medication-free intervals 146,
race!", affective symptoms!", increasing age and female sex!". The
expression of EPS also significantly increases the risk of developing TO at a later
stage138.
Clozapine was the first antipsychotic medication with a proven, reduced risk for
inducing T0149and it has even been suggested that this medication may, in fact,
treat T0150:151.It therefore seems logical that, as other second-generation
antipsychotic medications are also less likely to cause EPS than first generation
medications, their risk for causing TO will be lower152.In support of this notion, a
review of long-term studies show the risk of tardive dyskinesia to be substantially
lower with olanzapine than with haloperidol153.However, other authors have
argued that the evidence for this remains preliminary and inconclusive 154.
Another possible way to minimize the risk of TO would be to use first generation
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anti psychotics in low doses, thereby reducing their risk of causing EPS and,
perhaps, T0155,
Although the low-dose strategy is not necessarily clear-cut as a solution to the
problem, Owens 152 suggests it as prudent that "doses of antipsychotics in all
phases of treatment must be kept to the minimum necessary to achieve the
primary aims of the management pian," (p215)
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Chapter 6
Prolactin
Prolactin is a polypetide hormone synthesized by and excreted from the anterior
pituitary gland. Its principal role in human physiology is to induce and promote
milk production.
Prolactin secretion is controlled by complex mechanisms, of which dopamine is
the principal inhibitory component. This inhibitory effect is mediated via the
tubero-infundibular dopaminergic pathway156. Prolactin secretion is promoted by
various factors, including oestrogens (and, of course, the removal of the
inhibitory tone of dopamine). Serotonin also stimulates prolactin secretion. It
achieves this by at least two mechanisms: by inhibiting the effect of dopamine
and by increasing the activity of prolactin-secreting factors.
According to a number of studies, normal serum concentrations of prolactin in
men and non-pregnant, non-lactating females are between 5 - 25 ng/mI157;158.
Measuring prolactin is, however, not a simple endeavour: the levels of the
hormone vary considerably among individuals, but also have pronounced
circadian variation and even some seasonal variation. Furthermore, the circadian
variation of prolactin secretion depends primarily on sleep, rather than on an
intrinsic rhythm.
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Studies on patients with schizophrenia, who are not taking antipsychotic
medication, show that prolactin levels are normal in these subjects 159.
Treatment with first-generation antipsychotics has a profound effect on prolactin
levels, producing increases of around two to three times above the norm in the
majority of patlentsl". There are however, individual cases that experience
increases far greater than this. These increases appear to be dose related,
particularly for haloperldol'" and are mediated via the effects on 02 receptors. In
a recent study by Kapur et a1162, small doses of haloperidol were added to an
existing treatment regime of clozapine. Prolactin levels were measured at
baseline and again 4-8 weeks after addition of the haloperidol. Receptor
occupancy was also measured with [(11)C]raclopride and positron emission
tomography imaging. It was found that the addition of haloperidol increased O2
receptor occupancy from 55% to 79% and also significantly increased the
prolactin level.
Increased prolactin levels caused by antipsychotics do not return to baseline
immediately on discontinuation of medication, but remain high for a period of
approximately two to three weeks 163. However, there are some indications that a
subset of patients may develop tolerance to the prolactin-elevating effects of
antipsychotic medications 164.
The second-generation antipsychotic medications have much less of an effect on
prolactin, although there are great differences between different compounds.
Clozapine has little, if any, effect on prolactin 165, while olanzapine produces a
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transient increase in prolactin levels166. With risperidone, the effect is largely
dose-dependent, with higher doses causing a marked increase in prolactin
levels167. Quetiapine does not seem to have any effect on prolactin, eitherear1y
or later in treatmentl'".
The effects of hyperprolactinaemia
Patients with schizophrenia show lower levels of sexual interest and activity than
normal controls, even in the premorbid, unmedicated state168• Although treatment
of psychosis may improve social behaviour and, by implication, also sexual
behaviour, elevated prolactin levels are well-known to disturb sexual activity in
terms of desire, erection and orgasm in the male and may even cause
hypogonadism 169.
A study by Ghadirian et al170 showed that, although also high, complaints of
sexual dysfunction were considerably lower in women (30%) with elevated
prolactin levels than in men (81%). However, there are indications from this and
other studies that elevated levels of prolactin in females cause menstrual
disturbances and galactorrhoea.
Bone loss and osteoporosis is another area of concern in patients with
hyperprolactinaemia. There is considerable evidence that high levels of prolactin
are associated with reduced bone density171. This does not seem to be a direct
consequence of the elevated prolactin levels though, but rather secondary to
amenorrhoea and reduction in gonadal function. Reduction in bone density as a
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result of treatment with antipsychotic medication has been shown in both men
and women 172.
In conclusion, first-generation antipsychotics are known to elevate serum
prolactin levels, thereby causing sexual dysfunction (particularly in men) and loss
of bone density. There have also been reports that this increase in prolactin may
increase the risk for breast cancer!". Treatment options for hyperprolactinaemia
as a result of antipsychotic medication have been to either reduce the dose or to
treat the patient with a prolactin-lowering agent sum as bromocriptine,
cabergoline or amantadine 166.
The data with second-generation antipsychotics is less clear, but clozapine,
olanzapine and quetiapine seem to have very little risk in this regard.
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Chapter 7
Haloperidol
Paul Jansen from Belgium introduced haloperidol to the world in the middle of
the previous century. It proved to be a very powerful antipsychotic medication,
with less sedative effect than chlorpromazine. The original antipsychotics were
considered "dirty" medications, which did not only affect the 02 receptor (the
desired effect), but also a number of other receptors, such as muscarinic
cholinergic receptors, alpha adrenoreceptors and others (undesired effects).
It was therefore considered a major step forward when high potency O2receptor
antagonists such as haloperidol were introduced to the market. The more specific
the action of a medication on the O2receptor, the safer and more tolerable it was
considered to be. In time, haloperidol became the most widely used antipsychotic
medication in the world.
Haloperidol is a butyrophone derivative, a purely synthetic product and the first of
the butyrophenone series of major tranquilizers.
Chemical structure
Haloperidol's chemical structure is: C21H23C1FN02and it has a molecular weight
of 375.9173.It's chemical name is: 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-
fluorobutyrophenone. It has a pKa of 8.3.
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Haloperidol is insoluble in water, but is soluble in alcohol, chloroform, methanol-
acetone and benzene.
Pharmacokinetics 174;175:
Haloperidol is readily absorbed from the gastro-intestinal tract and is extensively
metabolized by the liver in the first-pass effect. There is wide intersubject
variation in plasma concentration. Haloperidol is highly bound to plasma proteins
(>90%). It is widely distributed in the body and crosses both the placenta and the
blood-brain barrier. Its volume of distribution is 18 I/kg.
Haloperidol has a half-life of 13-40 hours (mean 20 hours) and is metabolised
primarily by the liver. Systemic clearance is 11,8 ml/min/kg. This rate is increased
in children and reduced in the elderly. Haloperidol is excreted via urine (26%) as
well as via bile and faeces. Enterohepatic recycling of about 40% occurs.
Indications
Although haloperidol is best known as an antipsychotic medication that is used in
the treatment of schizophrenia or psychotic mood disorders, it is also indicated
for the treatment of Tourette's disorder, hiccups and agitated and aggressive
behavioural disturbances 176.
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Contra-indications
Haloperidol is contra-indicated in comatose states, Parkinson's disease and in
late pregnancy. It should also be used with caution in patients with
hyperthyroidism and in patients on lithium 177.
Haloperidol in the treatment of schizophrenia
Although haloperidol is clearly an effective antipsychotic, there are at least 2
major problems with this medication:
a) It is not universally effective and a substantial portion of patients show partial,
poor or no response to this medication.
b) It has the potential to produce serious side effects, some of which may be
irreversible (tardive dyskinesia) while others may be fatal (neuroleptic
malignant syndrome).
Even so, because of its relative safety, it is often used as a comparator in clinical
trials and has become the gold standard of antispychotics 178.
In a recent Cochrane review of haloperidol in the treatment of schizophrenia,
comment was made however, on the lack of data available on this compound!".
This review showed that, although haloperidol is a markedly effective
antipsychotic medication with a Number Needed To Treat (NNT) of only 3, it has
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a high risk of causing untoward effects, such as dystonia (1 in 5), akathisia (1 in
6) and parkinsonism (1 in 3).
The authors conclude that, although effective, other anti psychotics should be
chosen before haloperidol. They furthermore suggest that its initial cost-saving
effect (due to low direct acquisition cost) may be offset by the consequences of
adverse events, including poor compliance.
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Chapter 8
The Case for lower doses
The first antipsychotic medication synthesized was chlorpromazine, first used in
anaesthesiology in France in the early 1950's. When its antipsychotic effect was
reported by Delay and Deniker, it presented psychiatry with the first real tools for
treating severe mental illness, offering hope to many 1•
However, as experience with the earliest antipsychotics increased, the limitations
of these medications became clear. Whereas they were effective in relieving the
positive symptoms in 70% of patients 179 they brought with them a series of side
effects that would become the hallmark of antipsychotic treatment over the next
40 years. Extrapyramidal side-effects (EPS) of parkinsonism, akathisia, dystonia
and tardive dyskinesia were soon recognised by patients and clinicians alike as
the single, largest drawback of the antipsychotics. Additional problems included
sedation, weight gain, orthostatic hypotension and other cardiovascular side
effects. Furthermore, these medications were found to be less effective in the
treatment of the negative symptoms of the illness 180.
Although antipsychotics therefore have undisputed, beneficial effects on many
aspects of psychosis, patients often experience treatment as unwanted,
uncomfortable and preferably to be avoided. They are often sceptical about
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treatment, with high levels of non-compliance (up to 60% on oral medication 181
and 40% on depot medication 182). Among the reasons for negative attitude to
treatment are:
1. Poor insight into the disease
2. Poor doctor-patient interaction and
3. Societal prejudice against drug treatment for mental problems 183.
4. However, the single, most important contributing factor to non-compliance
remains the side-effects of antipsychotic medication131;132.
We therefore have treatments that help our patients, but only to a limited degree.
Patients are still left impaired in many areas of functioning. Also, the side effects
of these medications leave many patients unwilling and unlikely to take them
over the extended periods required.
As many patients fail to show response in their psychotic state in the early part of
treatment with antipsychotic medication, clinicians have tended to increase doses
of neuroleptics rapidly, hoping to accelerate the rate of improvement. In 1994, the
Royal College of Psychiatrists published a consensus statement'?', warning
against the use of high doses of antipsychotics and pointing to the dangers
inherent in this practice. These dangers include sudden cardiac deaths,
neuroleptic malignant syndrome, respiratory depression and others. Other
authors 185 have also suggested the use of effective, but minimum doses of
antipsychotics. Even so, high doses of antipsychotics are still employed in the
treatment of psychotic illness in many hospitals. Recent evidence has once again
shown that a reappraisal of traditional prescribing habits is imperative and that
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careful reconsideration of the dose-effect characteristics of traditional
antipsychotics may enhance their clinical use, reduce iatrogenic morbidity and,
ultimately, improve the quality of life of patients.
In a comprehensive survey of dose-effect relationships in treatment of psychosis,
Baldessarini et al79 did not find any support for the use of antipsychotics in high
doses above 500 -600 mg chlorpromazine equivalents. They suggested that
rapid neuroleptization and other forms of high dose treatment, which gained
prominence in the 1970's, may lead to continued and detrimental overtreatment
in patients who would have responded to moderate doses of medication, given
enough time for the full effect of the lower dose to take effect.
Other authors have gone even further: Van Putten et al82 found that patients who
received 20mg of haloperidol per day, did significantly worse than those receiving
10mg per day on a variety of measures, with significant deterioration on some
BPRS items as well as akinesia and akathisia ratings. Furthermore, 35% of their
patients receiving 20 mg of haloperidol per day insisted on leaving the hospital
against medical advice, as opposed to only 4% of those receiving 5 or 10 mg per
day. They suggested that high doses of haloperidol might have significant
psychotoxic effects and proposed doses as low as 5 mg per day after the first 2
weeks of treatment. Other studies have also borne out this finding, showing
clearly that doses of haloperidol above 10mg per day have no added clinical
benefit and in fact may be less effective than lower doses80;81 •
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McEvoy et al61 revisited the concept of "neuroleptic threshold" in 1991.
Neuroleptic threshold (NT) was defined as the lowest neuroleptic dose at which
individual patients develop slight increases in rigidity on neurological
examination. Using this construct, it was found that the mean haloperidol dose at
which their 106 patients crossed the NT was 3,7 mg per day. Of 58 patients
exposed only to NT doses of haloperidol, 72% clinically recovered within the 5-
week trial. Further increases in dose given to other patients did not lead to
greater improvent in psychosis, only to significant increases in EPS. They also
pointed to a significant difference in the dose required to reach neuroleptic
threshold in neuroleptic-naive patients (median 2 mg) versus previously exposed
patients (median 4 mg).
Some studies of maintenance treatment show similar results to the acute-phase
studies. Eklund and Forsman 186 conducted a study of 56 patients of whom 41
were randomized into treatment with haloperidol decanoate (HO) injection or
placebo for 48 weeks of double-blind treatment. Patients receiving HO were
given doses of 60mg every 4 weeks, corresponding to a daily dose of
approximately 3,6mg of oral haloperidol per day. Their results showed that these
low doses of HO prevented relapse in a majority of patients, with minimal
subjectively experiended side effects that differed only slightly from placebo
patients.
Modern research tools like PET have also helped to add more impetus to the
argument in favour of low-dose treatment. It is known that EPS is the result of 02
receptor occupancy in the basal ganglia and that typical antipsychotics block O2
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receptors in direct correlation to their clinical potency!". Some authors of PET
studies have suggested a threshold of around 70-80% O2receptor occupancy for
the introduction of EPS, which seems to be higher than the threshold for
antipsychotic effect121.
Recently, Kapur et aI109;188-190found in a series of PET studies that high levels of
O2occupancy could be achieved at very low doses of haloperidol. In one study,
seven patients with schizophrenia were treated with 2 mg per day of haloperidol.
PET showed 02 receptor occupancy of ranging from 53% to 74%, with 5 patients
showing substantial clinincal improvement. None of these patients showed
important side effects. In another study by the same group190,it was
demonstrated that 2 - 5mg of haloperidol would be expected to induce 60 - 80%
O2receptor occupancy, suggesting that the conventional use of more than 10mg
per day of haloperidol may be too high.
Looking at the evidence from another angle, the issue of plasma levels should be
considered. Although no clear evidence for a relationship between plasma levels
of haloperidol and clinical response have been found, a number of studies83;191
have identified plasma levels above which no further improvement is likely to
occur and where further increases may actually be detrimental. A recently
published study192showed that patients treated with haloperidol at plasma levels
above 25ng/ml did significantly worse than those treated with doses lower than
18ng/ml, providing more compelling evidence that higher doses offer no
additional benefit.
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Not all of the evidence supports the use of low-dose conventional anfipsychotics
however, with some suggesting poorer efficacy for low-dose oral 92 or depot 51
medication. In the study by Zimbroff et a192,haloperidol 4mg, 8mg and 16 mg per
day was compared to sertindole 12mg, 20mg and 24 mg in the treatment of
schizophrenia in a 8 -week, placebo-controlled, double-blind study. Although this
study found that both medications were effective in the treatment of psychosis,
haloperidol 4mg per day was not more effective than placebo on the final Clinical
Global Impression (CGI). Also, the 8mg dose of haloperidol seemed to be the
most effective dose in terms of all parameters. The study also found a fairly high
rate of parkinsonism and akathisia with haloperidol, even at the 4mg per day
level. The authors concluded that 4mg could be the minimally effective dose of
haloperidol. What makes this study so significant, is the fact that this was the first
multicentre, placebo-controlled assessment of the dose-response effects of
haloperidol, despite it's use over many years as a standard reference in clinical
trials.
The evidence from First-Episode Studies
As evidence accumulated that high doses of antipsychotic medication did not
lead to more effective or rapid treatment, and EPS was found to be the principal
cause of non-compliance 131, the practice of "rapid neuroleptization" lost favour in
most centres of influence. Many clinicians came to realize that lower doses of
antipsychotic medications might be even more important in neuroleptic-naïve
patients than in patients with chronic psychotic illness. Doses far below those
traditionally prescribed were reported in a few studies over the last
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decade61;62;90;92, with a number of other authors adding their voices in editorials
and books88;89;133;193.
In his classic study of the neuroleptic threshold, McEvol1 showed that patients
with a first-episode of psychosis needed only half the daily dose of haloperidol
required by patients with a more chronic illness. This is truly important, as the
standard practices still do not reflect this finding. Furthermore, internationally
accepted recommendations such as the PORT recornmendations'", although
considerably more conservative than previous guidelines, still suggest a daily
dose of 6 - 20mg of haloperidol.
More recently, Emsley et al90 conducted a 6-week, double blind study in patients
with first-episode psychosis in which risperidone was compared to haloperidol. In
this study, patients started medication at 2mg twice daily. The medication could
be titrated up or down in increments of 2mg. Maximum daily dose allowed was
8mg twice daily. At the end of the study, it was found that the mean daily dose of
risperidone was 6.1mg and that of haloperidol 5.6mg. This paper also points to
the particular importance of the dosing issue, in the light of previous work that
showed that patients in the ear1yphases of psychotic illness are more prone to
EPS than patients with more chronic illness.
Another study that proposed to find the "optimal" dose of haloperidol for first-
episode psychosis was conducted by Zhang-Wong et a162,which has already
been discussed (see chapter 3). Although this was a fairly brief study over only
four weeks with a smallish sampe size of only 36 patients, they showed again
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that the median optimal dose for the group as a whole was 5mg per day, which is
considerably lower than the doses normally used.
What remains problematic though, is that most of these are brief studies of the
treatment of first-episode psychosis, in the acute phase, over a period of only a
few weeks. Consider then the New York group's finding that the median time to
response in first-episode psychosis is 9 weeks59• This time lapse to response
becomes even more meaningful when we realize that, in that study, they used
doses far in excess of what would be considered acceptable today. It should be
self-evident that blinded, randomized, but relatively brief studies, although very
important, tell us perhaps too little of the "real" world, and should be interpreted
with caution. Clearly, acute phase studies where medication is titrated up after
just a few days will not take into consideration the adaptation that has to take
place in gene expression 194 and the proven, slow response rate to treatment.
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Chapter 9
The case for and against second generation anti psychotics
The re-approval of clozapine in the USA in 1989 marked the start of the "atypical
era". This medication was shown to be more effective than the first generation
medications in the treatment of both positive and negative symptoms of
schizophrenia, particularly in those patients refractory to standard treatments.
Importantly, it did so without the risk of EPS195. Unfortunately, clozapine's
potential for causing agranulocytosis limits it's utility to those patients with proven
treatment resistance. Despite this, it remains the gold standard against which all
new anti psychotics should be compared.
Since the "rediscovery" of clozapine, the field of psychiatry has witnessed an
unprecedented flood of new products to the antipsychotic market. All of these
medications have one thing in common: in clinical trials comparing them to first-
generation antipsychotics, they proved to cause fewer EPS. Thus this new class
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of medications have become known as the second generation of antipsychotic
medications.
The second-generation antipsychotics (also called "atypical" or "novel"
antipsychotics) do not however, represent a homogeneous class of medications.
In fact, even the definition of so-called "atypicality" is somewhat obscure. By the
most conservative definition, a medication can be considered atypical based on
the following three pharmacological and clinical criteria 196:
1. Antagonism of both D2 and 5HT2A receptors
2. Lower risk of causing EPS than first-generation antipsychotics
3. As effective in the treatment of positive symptoms as first-generation
antipsychotics.
But there is much more to the issue of second-generation antipsychotics than
just these three factors. They have also brought with them the hope of enhanced
clinical efficacy197. First-generation antipsychotics, although effective in treating
the positive symptoms of schizophrenia in a majority of patients, show limited
efficacy in treating the negative symptoms of the disorder''" and are only
minimally effective or ineffective in treating the cognitive symptoms thereof199.
Furthermore, the side effect profiles of the first-generation medications limit
patient compliance 131, leading to recurrence of illness and impacting negatively
on prognosis.
63
Stellenbosch University http://scholar.sun.ac.za
The next second-generation antipsychotic medication (after clozapine) was
introduced in 1994, with the marketing of risperidone (Risperdal®). The great
advantage of this medication over clozapine was the absence of the risk of
agranulocytosis. Since then olanzapine, quetiapine, sertindole, ziprasidone,
amisulpiride and others have been introduced to the market.
Although these medications are grouped together as "second-generation
antipsychotics", and even if there are some similarities in pharmacological
profiles, these are very different compounds with vastly different receptor binding
abilties. As already mentioned, they share the D2-blocking mechanism with the
first-generation antipsychotics, but also have the additional property of potent
5HT2A antagonism. For the rest, they exhibit significant differences in activity at
other receptor sites, such as the histaminergic, cholinergic and other
serotonergic sites.
Clinical effects of second-generation anti psychotics
Positive symptoms
In short-term studies over 4-6 weeks, each of the second-generation
antipsychotics has been proven to be as effective as the first-generation
antipsychotics in treating the positive symptoms of schizophrenia92;2oo-202.Some
studies even suggest superiority for the second-generation anti psychotics in
treating positive symptoms of schizophrenia over first generation
antipsychotics203-2o5.
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Negative symptoms
All antipsychotics treat negative symptoms, but do so to a lesser degree than
positive symptoms. The effect of antipsychotic medications on negative
symptoms is, however a highly complex and contentious issue. This complexity
arises form the difficulty in defining negative sympoms and its different
components, as well as the risk that side effects of medication may indeed make
the negative symptoms worse33. Therefore, some medications may at the same
time treat and exacerbate the negative symptoms of schizophrenia.
There has been substantial evidence over the last few years to show that the
second-generation antipsychotics are more effective in treating the negative
symptoms of schizophrenia than the first generation antipsychotics. The most
robust evidence here, once again, is for clozapine206. However, there have also
been publications showing superior efficacy for other second-generation
anti psychotics over first-generation antipsychotics in the treatment of negative
symptoms92;207. Despite the results presented and the arguments put forward in
sophisticated path analysis studies207, it remains possible that these medications
do not have any impact on the "core" or primary negative features of the
dlsorder!". It is possible that their seemingly greater efficacy in treating negative
symptoms result from the lower risk of EPS. In the case of clozapine, Carpenter
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has argued that a superior effect on positive symptoms may explain the apparent
change in negative symptoms208• The effect of second-generation versus first-
generation antipsychotics in the treatment of negative symptoms remains,
therefore, a controversial issue that will continue to be debated for some time205•
Cognitive symptoms
As pointed out before, cognitive deficits are not only key features of
schizophrenia, but have also been found to be the most important indicators of
social and vocational re-lnteqratlon". First generation antipsychotics seem
particularly poorly designed to treat these symptorns''".
Evidence with the second generation antipsychotics show that there are
improvements in attention and verbal working memory with rlsperldoneê'", and of
verbal production, visuomotor tracking and immediate verbal recall with
clozaplne?" and 0lanzapine212•
Side -effects
There is robust evidence that the second generation antipsychotic medications
produce fewer EPS at recommended doses than the first generation
antipsychotics90;2oo;201. This is again particularly true in the case of clozapine,
where no EPS have been reported, even at high doses. However, similar findings
have been made with the other second-generation antipsychotics, the
mechanism of which is discussed elsewhere.
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More recently however, more and more attention has been focused on side
effects other than the neurological, for which the first generation antipsychotics
have become so notorious. For example, a whole literature has developed
around the single issue of weight gain secondary to the use of certain second-
generation antipsychotic medications. This effect, together with the related effect
on glycaemic control, have become major issues in the literature on the
pharmacological treatment of psychosis213-215.It seems that second-generation
antipsychotic medications vary in their weight gain liabilities and that clozapine
and olanzapine are the two compounds that cause the most weight gain.
Despite the large literature suggesting superiority of the second-generation
antipsychotic medications over the first generation anti psychotics, there have
been some notable, dissenting voices. The arguments of those opposing the
unequivocal acceptance of the second-generation antipsychotics' superiority are
based in two broad principles:
a) Virtually all papers produced on the effects of second-generation
antipsychotics are industry-sponsored (see chapter 9).
b) Trials of second generation versus first generation antipsychotic medications
use the latter (particularly haloperidol) in doses that would ensure occurrence
of EPS and other side effects.
In a recent paper, Geddes et a1154conducted a systematic review of
effectiveness and tolerability studies of second- versus first-generation
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antipsychotics in the treatment of schizophrenia. However, in this study they also
evaluated the effect of the dose of the comparator medication (in this case
haloperidol), which they deemed important in evaluating the two parameters of
outcome. The results of this meta-analysis showed that, when they controlled for
the use of higher than the recommended dose of conventional (first-generation)
antipsychotics in many studies, there was only a modest difference in favour of
the second-generation antipsychotics in terms of EPS. Surprisingly however,
there were no differences in overall efficacy and tolerabililty between the two
groups. The authors go on to suggest that the "perceived benefits of atypical
anti psychotics are really due to excessive doses of the comparator drug used in
the trials."
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Chapter 10
Purpose of this study
Studies with new, second-generation antipsychotics seem to suggest superior
efficacy over haloperidol in the treatment of negative symptoms and mood and
related symptoms. However, these studies used haloperidol in doses well in
excess of 10mg per dajOO;204, thereby creating a study environment biased to
poor outcome in the haloperidol arm. This is true particularly in terms of side
effects, but probably also in negative symptoms and even mood symptoms.
One of the most interesting - and controversial - developments in medicine in
the last few years has been the very active participation of pharmaceutical
companies in the field of research publications. A large number of papers
published in the most prestigious journals are of studies sponsored by large
multi-national pharmaceutical companies. This has lead to growing scepticism
and a feeling among some scientists that this may be a form of covert
advertising, rather than objective science216;217. It has indeed been confusing to
some extent, as so many claims and counter-claims are published that the
clinician has to be extremely well read to remain abe to form an unbiased
opinion.
Psychopharmacology has been no exception to this phenomenon. In the highly
competitive marketplace for antipsychotic medication, it is often very clear that
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the outcome of a study is determined even before the first patient is screened by
a protocol that is "set up to win." It is marketplace common sense, and not
scientific ethos or lack thereof, that lead pharmaceutical companies only to
sponsor studies where a positive outcome for their product is likely.
Although it is therefore important to compare antipsychotics to determine
differences in efficacy and side-effect profiles, we (as the scientific community)
must be certain that we are comparing like to like: the issue of equivalent doses
has, in our mind, not received enough attention in "head-to-head" studies,
particularly those using haloperidol. To illustrate this point, let us consider a
recent studj18 with two of the second-generation antipsychotic medications.
Here olanzapine was found to be superior to risperidone on a variety of
measures, among them treatment of negative symptoms. It must be noted that
the doses of risperidone used in this study were titrated up to 6 mg per day within
3 days and that the mean modal dose of risperidone used in this study was
7,2mg per day. Now consider the fact that the chlorpromazine equivalence for
risperidone is reported to be 1: 100 (i.e. 1mg of risperidone = 100mg
chlorpromazine). Thus the chlorpromazine equivalents of risperidone used in this
study was 720mg per day, far exceeding Baldessarlni's/'' recommended
maximum of 500 --600 mg chlorpromazine equivalents! For haloperidol, this
factor must also be taken into account. Chlorpromazine equivalency for
haloperidd is often not very clear, but seems to be in the region of 1:100 (1 mg
haloperidd = 100 mg chlorpromazine), therefore doses in excess of 10mg per
day would be far more than 500mg chlorpromazine equivalents.
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With new technologies like single photon emission tomography (SPEeT) and
PET, as well as better-designed clinical trials, researchers should be able to
generate more useful and accurate information on dosing of medication than
ever before. However, with patents having expired long ago, pharmaceutical
companies have very little incentive to spend money on research into the first-
generation antipsychotics, unless it is to use them as comparator drugs against
which to test their new molecules. Although these studies may at times
serindipitously yield important information about the older rnedications'", it is
more likely than not that they are used as flogging horses against which to show
off a new product.
In spite of a number of dissenting voices who claim that the second generation
antipsychotics offer very little, if any benefits over first-generation medications 154,
the first world seems to have largely abandoned the use of the first-generation
anti psychotics in favour of the more user-friendly second-generation medications.
In the developing world (including South Africa) however, this choice is not yet
available 133.
It seems nothing less than ironic that most of the arguments regarding the
relative merits of the first- versus the second-generation antipsychotics are based
on comparisons to haloperidol when there is so little information available on the
correct dosing of this medication. To this day, the "correct dose" of haloperidol
remains largely the prerogative of the clinician or researcher. With the focus of
research on the second-generation medications, it also seems unlikely that
researchers in the first world will undertake large-scale studies to determine to
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the correct dosing schedule for haloperidol. However, as it remains the
antipsychotic of choice for most patients in the developing world, finding the
correct dose of this medication continues to be of great importance.
In psychopharmacology research, the double blind, placebcrcontrolled, fixed
dose study has become the gold standard. This has helped tremendously in
providing unbiased information in clinical research. However, some of the
problems with this kind of research are that protocols have very restrictive
inclusion and exclusion criteria and often treat only a selected few patients for a
very limited time. These studies invariably also have substantial dropout rates
and provide more information on efficacy (a measure of the ability of the drug to
treat whatever condition it is indicated for), rather than effectiveness
(encompassing efficacy as well as tolerability and ease of use). Although
therefore providing statistically pure data, they are often of limited value to the
clinician who has to deal with patients with multiple pathologies, unclear
diagnoses, co-morbid substance abuse and poor compliance over extended
periods .
.It is therefore also of importance to do naturalistic studies where researchers
attempt to approach the clinical setting, while adhering to sound research
principals. These studies may be of greater clinical relevance that the double
blind, fixed dose studies over a few weeks.
In the case of haloperidol in particular, the fixed dose studies are problematical.
With wide inter-individual dose:plasma level variance, fixed-dose studies with this
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medication may often result in unsatisfactory, biased data. As stated before, this
medication has high affinity for the dopamine D2-receptor, with an extremely
narrow therapeutic index. Finding the "therapeutic window" in a particular patient
should be an individual process, as there are so many factors that may
eventually influence the concentration of the medication at the receptor site.
Considering the abovementioned, the purpose of this study was twofold:
1. Firstly, it was decided to use a naturalistic design to do a dose-ranging study
in patients with first-episode psychosis. This arm of the study would therefore
aim to determine the mean effective dose of haloperidol in patients
experiencing a first psychotic breakdown. The mean effective dose would be
the dose at which patients have response in psychotic symptoms, without
unacceptable EPS or other side effects.
2. The second arm of the study would then compare this dose determined in the
first part of the study with the standard dose of haloperidol. This was
somewhat of a problem, as there were no "standard" doses to compare it
with. The only "dose-finding" study that we could find with haloperidol was the
sertindole study by Zimbroff et a192,which showed haloperidol 8mg per day to
be the most effective dose. It was therefore decided that 8mg would be used
as the comparator dose.
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Chapter 11
Subjects and method
Subjects were recruited from the Tygerberg-Stikland academic complex of
hospitals. Both of these hospitals are affiliated with the University of Stellenbosch
in Cape Town, South Africa. Subjects were recruited from the wards (i.e.
insubjects), from the outsubjects department of the hospitals, as well as the clinic
system and day hospitals within the hospitals' catchment area. Ethics approval
was obtained through the ethics committee of the University of Stellenbosch. All
subjects signed written, informed consent before any study-related procedures
were undertaken.
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All subjects were evaluated by Dr. P. Oosthuizen, who acted as the principal
investigator. Dr. J.H. Turner acted as co-investigator and evaluated subjects
when Dr. Oosthuizen was not available. These two investigators participated in
regular interrater-reliability training sessions and a high level of interrater-
reliability was maintained.
The following inclusion and exclusion criteria were applied:
Inclusion criteria
1. Male or female in- or outpatients.
2. Aged between 14 and 55 years. (inclusive)
3. DSM-IV diagnosis of schizophreniform disorder, or diagnosis of
schizophrenia or schizo-affective disorder.
4. Current psychotic symptoms requiring antipsychotic treatment,
in the opinion of the investigator.
5. Subjects who had, during their lifetime, been exposed to a
maximum of 4 weeks of neuroleptic medication (This is,
according to international protocol, the most practical cut-off
point. More exposure to neuroleptics than this could
significantly change some of the variables that we are
measuring. )
6. Subject and/or legal guardian or representative has signed the
informed consent form, according to the regulations of the
ethics committee/so
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Exclusion criteria
Subjects meeting one or more of the following criteria could not be
entered:
1. Evidence of alcohol or drug abuse in the last month before
screening.
2. Subjects who had been treated with a long-acting depot
neuroleptic.
3. Serious physical illness.
4. Mental retardation.
Withdrawal criteria
Subjects could be withdrawn from the study if:
1. The investigator considered it, for safety or efficacy reasons, in
the best interest of the subject that he/she be withdrawn.
2. The subject withdrew his/her consent.
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At baseline, after informed consent, the following information was obtained from
the subject and/or guardian (All information was noted on a standardized form
according to a semi-structured interview):
Demographic Data
Personal History
Psychiatric History
Medical History
Family History
History of previous treatment
History of concomitant medication
Each subject had a full physical examination at baseline, including a neurological
evaluation.
Phase 1
Each subject had the following rating scales administered at baseline:
SCID (Structured Clinical Interview for DSM_IV)219
PANSS (Positive and Negative Symptom Scale)27
CGI (Clinical Globallmpression)22o
Y-BOCS (Yale-Brown Obsessive Compulsive Scale)221
Calgary Depression Rating Scale222
AIMS (Abnormal Involuntary Movement Scaley20
Barnes Akathisia Rating Scale223
Simpson-Angus Rating scale224
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A blood sample for analysis of prolactin levels was also obtained at baseline.
After baseline evaluation, each subject had 19 scheduled visits over a 2-year
period. Some subjects were seen more regularly due to unforseen events.
At each of these visits, subjects were evaluated with the following rating scales:
PANNS
CGI
CGI-CIS
Calgary Depression rating scale
AIMS
Barnes Akathisia Scale
Simpson-Angus Rating Scale
Diagnoses were re-evaluated at six-monthly intervals.
Prolactin levels were repeated at 6 weeks, 3 months, 6 months, 12 months, 18
months and 24 months.
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The treatment section of phase 1 of the study was a naturalistic, open-label study
according to a treatment algorithm. In this treatment algorithm, all subjects were
commenced on treatment with haloperidol 1mg per day. This dose was then
maintained for at least the first four weeks, unless there was a significant
deterioration in the subject's psychotic illness. If the subject's condition
deteriorated significantly, the dose could be increased by 1 mg at day 7/ visit 1
(i.e. to 2 mg)
At week 4, subjects were evaluated with the full battery of rating scales as
described above. If, at this point, the subject failed to show adequate response
(here defined as 20% improvement in PANSS Total Score), the dose of
haloperidd could be increased by 1 mg per week, until adequate response was
achieved or a maximum of 10mg haloperidol per day was reached. Subjects who
failed to improve on this dose could then:
a) Have a further increase in haloperidol up to a maximum of 20mg per day
b) Change over to thioridazine, starting on 100mg per day and increasing to
600mg per day
c) Change to clozapine
Although the protocol allowed 3 options, in practice all subjects who did not
respond at 10mg haloperidol were changed to thioridazine 100mg, increased
weekly by 100mg to 600mg and if there still was no response after 3 weeks on
600mg, changed to clozapne,
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The dose of haloperidol could be titrated down at any time and by any dose-
increment in the case of clinically significant treatment-emergent adverse events
and/or if, in the treating doctor's judgement, a decrease was warranted.
Lorazepam could be used throughout the study if additional sedation was
required. In case of acute disruptive behaviour that could not be contained within
the limits of the protocol, or other extra-ordinary circumstances, subjects were
allowed to "escape" the slow titration process, to allow for more rapid increase in
the dose of haloperidol.
Orphenadrine and/or biperidine were allowed throughout the study for the
treatment of EPS, if required. These medications were discontinued at the
earliest possible opportunity.
If persistent comorbid Axis-I disorders such as major depressive disorder or
obsessive-compulsive disorder were diagnosed, these were noted and treated.
Phase II
The second phase of the study was a double blind, randomised study of ultra-low
dose versus standard dose haloperidol. In this part of the study, we used the
clinical data obtained trom phase 1 to determine the dose of medication that we
would use. As the mean daily dose in the acute phase of the open label
treatment was approximately 1,78mg per day225,we decided to use 2mg per day
as the treatment dose. Haloperidol 8 mg per day was used as the reference
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medication. This was decided in the light of previous studies that suggested that
doses higher than 10mg may be detrimental to the subject's mental health83, and
as a result of the only proper "dose finding" study with haloperidol, that by
Zimbroff et a192•As discussed earlier, this study suggested 8mg per day to be the
optimal dose of haloperidol.
At baseline in this phase of the study, subjects were evaluated with the following
instruments:
SCID
PANSS
YBOCS
CGI
Calgary Depression Rating Scale
AIMS
Barnes Akthisia Rating Scale
Simpson Angus Rating Scale
Extrapyramidal Symptom Rating Scale226• This additional scale for the rating of
EPS was added for two reasons:
a) To improve the sensitivity of ratings
b) To improve across-study compatibility with other studies
After baseline, subjects were randomized using a randomization table into one of
the two treatment groups. Treatment was with identical-looking capsules,
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containing either haloperidol 2mg per capsule or haloperidol according to a
titration schedule (see table 12.1)
Table 11.1
Timelines for administration of double-blind medication during Phase II
2mg 4mg 6mg 8mg
Lorazepam was allowed as additional treatment for restless or agitated behaviour
throughout the study. Orphenadrine and/or biperidine were allowed for treatment-
emergent EPS. All concomitant medications were recorded.
Subjects were reassessed on a weekly basis, with the following rating scales:
PANSS
CGI
CGI-CIS
Calgary Depression Rating Scale
AIMS
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Barnes Akathisia Rating Scale
Simpson Angus Rating Scale
ESRS
Blood sampling for prolactin levels were done at baseline and at endpoint.
Statistical Analysis
Statistical analysis was performed with the help of a specialized computer
software package Statistica version 6 (Statsaft, Inc.). Dr. P. Oosthuizen
performed the analyses under the guidance of a qualified and experienced
medical statistician, Dr. MC Roberts.
An intent-to-treat design was used in this study, with last observation carried
forward (LOCF) for any subject who did not complete either phase of the study.
The primary measure of efficacy was the percentage change in PANSS total
score form baseline to endpoint. Secondary measures of efficacy were
percentage changes in PANSS subscale scores, as well as percentage changes
in side-effect ratings.
Categorical variables were compared using chi-square or Fisher's exact test
(two-tailed in all cases), depending on expected frequencies.
All numerical variables were first tested for normality of distribution using the
Kolmogorov-Smirnov method. In cases where unrelated groups were compared
in terms of numerical variables, we used either Student's t test (parametric) or
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the Mann-Whitney U test (non-parametric). For correlations between pairs of
numeric variables, we used either Pearson product moment correlation
coefficient (parametric), or the Spearman rank order correlation coefficient (non-
parametric).
As we were concemed that some of the results of the initial analysis of tardive
dyskinesia were confounded, we performed a second analysis. In this analysis,
Cox regression (also known as the proportional hazards method) was used to
determine the effects of predictor variables and risk factors on the occurrence of
TO. A significance level of 0.05 was used throughout.
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Chapter 12
Results: General
Demographics, family and personal history
A total of 97 subjects were included in the two phases of the study.
Fifty-seven subjects were included in the open-label phase of the study and 40
subjects in the double-blind phase of the study. Fifty-four subjects (55.7%) from
the combined group were male.
Age
The mean age at inclusion into the study was 28.3 years (± 8.3). The mean age
at inclusion for female subjects at 31.7 years (± 8.5) was older than that of male
subjects at 25.5 years (±7.0). This difference in age at inclusion was highly
statistically significant (t = 3.8; df = 87; P = 0.0003).
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Ethnic distribution
The ethnic distribution of subjects is shown below in figure 13.1. All of the
subjects, but one, were born in South Africa. The single exception was 1 female
subject who was born in the Netherlands.
Figure 12.1
Ethnic Distribution of subjects
• Mixed African-Caucasian
.Caucasian
IElAfrican
DOther
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Marital Status
We had reliable information on the marital status of 91 subjects.
Of these, 16 subjects were married at the time of inclusion into the study (6 male,
10 female); 5 females subject had been divorced. Seventy subjects had never
been married (45 male, 25 female). No subjects reported living in a de facto
relationship at the time of inclusion into the study. There were more than twice as
many females who had ever entered into marriage compared to males, a
statistically significant difference between the genders (chi-square = 8.36; df = 1;
P = 0.004). Marital status was not related to any of the psychopathology, side
effect or depression factor ratings and did not affect changes in psychopathology
or dose of medication used.
Fertility
We had reliable data on fertility rates for 87 subjects. Fifty-three subjects had
never had children.
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Table 12.1
Fertility Rates
1.2 (± 1.4) 1.5 (±1.6)
0.4(±0.8) 0.7(±1.1)
1.3(±1.5)
0.5 (±O.g)
Female subjects had a significantly greater number of children than male
subjects (t = 3.11; df = 85; P = 0.003).
Schooling
We had reliable information on the schooling of 83 subjects. Subjects left school
at the median age of 18 years. Subjects achieved on average a standard 8
(grade 10) education. One subject held a Master's Degree and one subject held
a Bachelor's degree at the time of inclusion into the study. There were no gender
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differences in levels of schooling. Three subjects were full-time students and one
a part-time student at the time of inclusion into the study.
Living arrangements/accommodation
Accommodation of subjects at inclusion into the study is presented below in table
12.2
Table 12.2
Accommodation of subjects at inclusion into study
1
2
6
9
25
6
2
1
2
6
19
2
3
3
8
15
44
8
Most subjects had been in their current accommodation for a considerable time,
with a mean period of 98.2 months in the accommodation where they stayed just
prior to admission (N = 83; Mean = 98.2; ±104.1 months)
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There were a mean number of 5.0 (±3.0) occupants per home and the mean
number of rooms per home (all rooms in the house, including kitchens and
bathrooms) was 5.0 (±2.2).
Ninety percent of subjects had contact with their family on a regular basis.
We obtained a reliable family history from 74 subjects. Of these, 29 subjects
(39.2%) had a positive family history of psychiatric illness.
Table 12.3
Family History of Psychiatric Illness
12
3
o
o
o
o
o
4
12
3
1
o
1
o
o
o
5
14
15
4
o
1
o
o
o
9
26
90
Stellenbosch University http://scholar.sun.ac.za
Employment History
Table 12.4 presents data regarding the employment status of subjects at
inclusion into the study:
Table 12.4
Employment status at inclusion into study
15
3
5
14
15%
3%
5%
14%
Of the 38 subjects in phase I who were unemployed at inclusion into the study,
18 (47.3%) had never been fully employed in their lifetime. Of the 22 unemployed
in phase 2, 11 (50%) had never been fully employed.
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Personal and birth history
We had reliable information on maternal age at birth of the index subject in only
54 cases. The mean age of the mothers at the birth of the baby was 27.33 years
(±6.1 years). Fathers were on average, about 4 years older (N = 55; mean = 31.6
years ± 9.4 years.)
Subjects came from fairly large families, with the mean number of siblings at 3.9
(±2.6).
Three male subjects and one female subject were known to be members of a set
of twins. In all cases, the other twin was unaffected at the time of inclusion of the
index subjects into the study.
Mother's health and lifestyle risks during pregnancy
The mothers of 3 subjects from phase I and 1 subject from phase II were
admitted to hospital during the index pregnancy. The reasons for admission
were:
Premature rupture of membranes in one case,
False labour in one case,
Severe oedema in one case
and threatening miscarriage in one case.
Four other mothers received medication during the index pregnancy - in three
cases the mothers received treatment with iron supplements and in one case the
mother received antihypertensives.
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Of the 97 subjects included, only 39 (40.2%) could confirm that their mothers
attended an antenatal clinic during the index pregnancy.
From the history alone, it seems that the subjects included in this study were all
born at, or close to, full-term (Mean period of gestation = 39.9 weeks, stdv = 0.35
weeks)
Table 12.5
Mother's lifestyle risks during pregnancy with index subject
21
11
7
o
2
1
39
19
9
o
2
1
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Table 12.6
Mother's health during pregnancy with subject
28
3
1
o
o
o
o
1
o
14
o
o
1
o
o
2
o
o
42
3
1
1
o
o
2
1
o
94
Stellenbosch University http://scholar.sun.ac.za
Table 12.7
Place of birth
4
5
12
2
25
3
1
7
2
23
7
6
19
4
48
Birth was induced in 9 cases (9%).
Thirty-six subjects were born as normal occipital presentations, whereas there
was one case of a breach presentation and one case of limb presentation
reported. Three subjects were born by caeserian section. Three subjects' births
were assisted (forceps), there were 8 cases of prolonged labour and 1 case of
vaginal tear during the birth process. Birth weight could not be assessed reliably,
due to poor record keeping and uncertainty about the reliability of information
obtained from caregivers.
Two subjects had to be resuscitated after birth, 7 were treated for jaundice and
spent more than a couple of hours in the incubator. There was only one report in
phase I of physical abnormality at birth. This was a subject who had a "growth"
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(no further information available) removed from the side of her head shortly after
birth. One subject in phase II reported a congenital abnormality of his left foot
and one subject was born with an extra finger.
Duration of untreated psychosis (DUP)
The mean delay in diagnosis and treatment from first onset of psychotic features
up to the day of first treatment is known as the duration of untreated psychosis
(DUP). The DUP for the whole group of subjects is presented below in table 12.8.
Table 12.8
Duration of untreated psychosis (all subjects) in days
44
37
390.1
305.6
842.9
494.3
We found no gender difference in DUP (t = -0.54; df = 79; P = 0.6). DUP also did
not show any significant correlation with any of the baseline psychopathology
scores or outcome scores in phase II of the study.
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However, in phase I, there was a significant, inverse correlation between DUP
and improvement in negative symptoms over 2 years (see table 12.9)
Table 12.9
Spearman Rank Order Correlation between DUP and Percentage
improvement in PANSS Negative Score over 24 months
* Significance at 0.05 level
0.006 0.045 0.964
-0.048 -0.333 0.740
0.028 0.197 0.845
-0.154 -1.079 0.286
-0.181 -1.276 0.208
-0.241 -1.718 0.092
-0.239 -1.708 0.094
-0.307 -2.237 0.030*
-0.318 -2.324 0.024*
Furthermore, the DUP also showed a significant inverse correlation with
percentage improvement of PANSS Total Score at 24 months in phase I (see
table 12.10)
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Table 12.10
Spearman Rank Order Correlation between DUP and Percentage
improvement in PANSS Total Score over 24 months
* Significance at 0.05 level
-0.12 -0.82 0.41
-0.14 -1.00 0.32
-0.07 -0.49 0.63
-0.19 -1.37 0.18
-0.25 -1.80 0.08
-0.27 -1.93 0.06
-0.21 -1.49 0.14
-0.26 -1.89 0.07
-0.29 -2.07 0.04*
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Chapter 13
Results: Phase I
Fifty-seven subjects were included in this phase of the study. Thirty-nine subjects
remained in the study for the first 12 months, and 28 subjects remained in the
study for the full 24 months. Eighteen subjects (32%) dropped out of the study
within the first 12 months. At the end of 24 months, a further 11 subjects had
dropped out of the study, leaving 28 to complete the 24-month evaluation. This
means that only 49.1% of subjects, who were included in the study, were seen at
24 months. Of the 29 subjects who had dropped out by 24 months, 23 were lost
to follow-up, 5 were withdrawn and 1 had died.
Drop-outs
Female subjects were more likely than male subjects to drop out of the study
within the first 12 months (t = -2.489; df=55; p=0.02) as well as over 24 months
(t= 2.75; df = 55; P = 0.008). In the first 12 months, 14 female subjects dropped
out of the study, compared to only 4 males. At 24 months, a total of 18 female
subjects had dropped out, compared to 11 male subjects.
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Figure 13.1
Cumulative Proportion Surviving in Study over 24 months
(Kaplan-Meier)
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Gender differences
Despite the difference in drop-outs, there were no significant gender differences
found in the following variables (all LOeF data):
Percentage change in PANSS Total Score and all subscale scores at 12 and
24 months.
Remission rates at 12 and 24 months.
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Dose of medication at 12 and 24 months.
Risk of relapse at 12 and 24 months.
EPS (as measured by the Simpson-Angus Score) at 12 months and 24
months.
Medication
After baseline evaluation, all patients were commenced on haloperidol at 1mg
per day. Doses were then adjusted according to protocol (see subjects and
method section)
The mean dose of medication over 24 months (LOeF) are reported below in
table 13.1.
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Table 13.1
Mean dose of haloperidol (mg/day)
54 1.5 0.7
53 1.6 0.9
50 1.7 1.2
48 1.6 1.0
48 1.7 1.0
46 1.6 1.1
46 1.3 0.7
45 1.3 1.0
44 1.3 0.8
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Psychopathology
Baseline, 12 month and 24 month scores on the PANSS Total and subscale
scores are tabulated below:
Table 13.2
Psychopathology scores at baseline, 12 month and 24 month follow-up
(LOeF)
11.8 (±5.9)
12.5 (±6.5)
16.4 (±6.7) 26.8 (±8.D)
17.6 (±7.6) 27.3 (±9.5)
54.9 (±17.3)
56.9 (±21.1)
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Changes in psychopathology
The percentage changes in PANSS Total and subscale scores were as follows
(all LOeF data):
Table 13.3
Percentage Change in Psychopathology Scores over 12 months and 24
months as measured with PANSS
26.34 (±30.67) 22.00 (±31.75)
37.16 (±20.62) 36.14 (±22.79)
39.80 (±19.7) 37.98 (±22.31)
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Figure 13.3
Change in PANSS Total Score over 24 months
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Figure 13.4
Percentage Improvement in PANSS Total and subscale scores over 24
months
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Mood symptoms
Mood symptoms in phase I were evaluated in two ways
a) The depression factor of the PANSS
b) The Calgary Depression Rating Scale
The depression factor of the PANSS
Here, depressive symptoms were measured by means of the depression factor
identified by Kay in his original factor analysis of the PANSS28. This factor
comprises the composite score for the PANSS items of somatic concern (G1),
anxiety (G2), guilt feelings (G3), and depression (G6)
Results are presented below in table 13.4.
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Table 13.4
PANSS Depression Factor Score over 24 Months (LOeF)
57 5.5 (±2.1)
57 5.4 (±2.3)
57 5.7 (±2.3)
57 5.4 (±2.1)
57 5.6 (±2.4)
57 5.6 (±2.4)
57 5.8 (±2.6)
57 5.5 (±2.6)
57 5.5 (±2.3)
We found no group differences in terms of mood score or changes in mood score
over time in terms of the following variables:
Gender
Race
Marital Status
Remission
There were however, group differences in the following variables:
109
Stellenbosch University http://scholar.sun.ac.za
Risk of relapse and depression factor score at 9 months (t = 2.03; df = 41; P =
0.049) and risk of relapse and depression factor score at 12 months (t = 2.4; df =
41; P = 0.02).
Risk of tardive dyskinesia and depression factor score at 6 months (see results in
section on tardive dyskinesia.)
We evaluated the correlation between the depression factor score and a number
of psychopathology variables. The only correlation that we found was between
the depression factor score at baseline and improvement in negative symptoms
over the first six months. Although it was no longer significant from 9 months
(with the exception of 18 months), the trend is still evident to the end of the study
(compare to results for Calgary Depression Scale).
Results are presented below in table 13.5 and figure 13.5.
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Table 13.5
Correlation between PANSS depression factor score and Percentage
Improvement in PANSS Negative Score
57 0.3 2.52 0.015*
57 0.3 2.30 0.025*
57 0.2 1.44 0.156
57 0.2 1.26 0.214
57 0.3 1.93 0.059
57 0.3 2.40 0.020*
57 0.2 1.81 0.076
57 0.2 1.82 0.075
*Significance at the 0.05 level
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The Calgary Depression Rating Scale
Similar analyses were performed with the Calgary Depression Rating Scale data
as with the PANSS depression factor. In terms of categorical variables, we found
only a difference in score on the Calgary scale at 12 months and the risk of
relapse by 12 months (t = 2.07; df = 41; P = 0.04). Subjects who relapsed
therefore were more likely to have a higher Calgary Score at 12 months, as could
be expected. This finding was not replicated with the data at 24 months.
Notably, we did not, in this analysis, find the difference in Calgary Score at
baseline between those who later developed TO and those who did not (see
section on TO).
When we analysed the data (as we did for the PANSS Depression Factor Score)
for correlations with parameters of psychopathology, findings were considerably
more robust. Here, the correlation between the Calgary Depression Score at
baseline and improvement in PANSS Negative Symptom Score was sustained
for the full 24 months. Furthermore, we also found a significant correlation
between the Calgary Depression Score at baseline and improvement in PANSS
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Positive Symptom Score, PANSS General Psychopathology Score and PANSS
Total Score. Results are presented below in table 13.6 and figure 13.6.
Table 13.6
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS Negative Score over 24 months
57 0.3 2.23 0.030*
57 0.3 2.60 0.013*
57 0.3 2.32 0.024*
57 0.3 2.04 0.046*
57 0.4 3.10 0.003*
57 0.4 3.43 0.001*
57 0.3 2.54 0.014*
57 0.3 2.46 0.017*
* Significance at the 0.05 level
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Figure 13.6
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS Negative Score over 24 months
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Table 13.7
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS Positive Score over 24 months
57 0.2 1.60 0.118
57 0.2 1.31 0.196
57 0.2 1.33 0.188
57 0.2 1.60 0.116
57 0.3 2.11 0.039*
57 0.3 2.63 0.011*
57 0.3 1.96 0.055
57 0.3 2.04 0.046*
* Significance at the 0.05 level
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Figure 13. 7
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS Positive Score over 24 months
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Table 13.8
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS General Psychopathology Score
over 24 months
0.4 2.89 0.006*
0.4 3.54 0.001*
0.4 2.88 0.006*
0.4 3.38 0.001*
0.5 4.02 0.000*
0.5 4.70 0.000*
0.5 3.97 0.000*
0.4 3.51 0.001*
* Significance at the 0.05 level
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Figure 13.8
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS General Psychopathology Score
over 24 months
6wks 3mnth. 6mnths 9mnth. 2mnth. 5mnth. 8mnths 1mnth. 4mnths
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Table 13.9
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS Total Score over 24 months
0.4 2.75 0.007*
0.4 3.00 0.004*
0.3 2.51 0.015*
0.3 2.32 0.024*
0.4 3.47 0.001*
0.5 4.23 0.000*
0.4 3.51 0.001*
0.4 3.05 0.003*
* Significance at the 0.05 level
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Figure 13.9
Correlation between Calgary Depression Rating Scale Score at Baseline
and Percentage improvement in PANSS Total Score over 24 months
6wkl 3mnthl 6mnths 9mnths 2mnths 5mnths 8mnths 1mnths 4mnths
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Remission
Subjects were considered to be in remission if they had no PANSS Positive
Subscale score> 3 and a rating of "Much improved" or "Very much improved on
the eGI Response Item. At the end of 12 months, 38 subjects (67%, LOeF data)
were considered to be in remission and at the end of 24 months, 39 subjects
were in remission (68%, LOeF data). We found no gender difference in rates of
remission at the end of 12 months (LOeF data: chi-square = 0.57; df = 1; P =
0.45) or 24 months (chi-square = 0.22, df = 1; P = 0.64).
Relapse
The first 12 months
Although 39 subjects completed the first 12 months of the study, a further 4
subjects who had earlier been lost to follow-up were seen at or around the time
of the 12 month visit. Therefore, we had relapse data on 43 subjects by 12
months.
11 Subjects relapsed within the first 12 months. This was equal to 19% of the
total group or 26% of the group where we had 12-month data available.
Of the subjects who relapsed, 9/11 (82%) are male. This did not however,
achieve statistical significance (p = .15; Fisher's exact test, two-tailed).
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Risk of relapse was not associated with any of the following variables:
Age
Dose of medication
Diagnosis
Tardive Dyskinesia
Risk of relapse at 12 months was, however associated with the following
variables:
PANSS Positive score at 12 months ( p = 0.02)
PANSS General Psychopathology Score at 12 months (p = 0.02)
Percentage change in PANSS Positive Subscore at 12 months (p = 0.01)
Depression factor score at 12 months (p = 0.005)
The direction of all of these associations was as would be expected, with
subjects who relapsed having higher scores on each of the variables compared
to those subjects who did not relapse.
For subjects who relapsed within the first 12 months, the following were judged to
be the principal causes of the relapse:
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Table 13.10
Relapse in phase I (12 month data)
Months 12 - 24
For this analysis, we used LOeF data from the first and second year. Seven
subjects relapsed in the second year. Of these, two subjects had more than one
relapse. Three of the 7 subjects, who relapsed in the second year, had also had
a relapse in the first year and 4 subjects relapsed for the first time in the second
year of treatment.
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There were no statistically significant differences between subjects who relapsed
by 24 months and those who did not in terms of the following variables:
Age
Gender
Marital status
Duration of untreated psychosis
Dose of medication at either 12 or 24 months
Risk of TO
Percentage change on any of the psychopathology scores at 24 months
Mood symptoms as evaluated by the Calgary Depression Rating Scale
For subjects who relapsed between 12 and 24 months, the following were judged
to be the principal causes of the relapse
Table 13.11
Relapse in phase I (data for year 2)
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Side-effect ratings
Extra-pyramidal side-effects
Parkinsonism
The mean scores for the Simpson Angus Rating Scale between baseline and 24
months are presented below in table 13.12:
Table 13.12
Mean scores on Simpson-Angus Rating Scale over 24 months
11.7 3.5
11.5 2.2
10.8 1.8
9 Months 10.7 1.2
12 Months 10.6 1.2
15 Months 10.5 1.3
18 Months 10.5 1.0
10.8 1.9
11.2 2.4
Baseline 10.9 1.5
6 Weeks 11.7 3.4
3 Months 11.5 2.2
6 Months 10.4 0.6
9 Months 10.3 0.7
12 Months 10.5 1.4
15 Months 10.1 0.2
18 Months 10.4 0.8
21 Months 10.3 0.6
24 Months 10.7 1.8
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Baseline 11.7 3.0
6 Weeks 11.7 3.5
3 Months 11.5 2.2
6 Months 11.3 2.5
9 Months 11.3 1.4
12 Months 10.6 1.0
15 Months 11.2 1.9
18 Months 10.7 1.3
21 Months 11.6 2.8
24 Months 11.8 3.1
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Figure 13.10
Mean scores on Simpson-Angus Rating Scale over 24 months
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Akathisia
Ratings for the Barnes Akathisia Rating Scale at different time points are
tabulated below. None of the changes were statistically significant:
Table 13.13
Mean Scores for Barnes Akathisia Rating Scale
Dyskinesia
12 Months 0.00 0.00
24 Months 0.11 0.46
Baseline 0.03 0.19
12 Months 0.00 0.00
24 Months 0.00 0.00
Baseline 0.04 0.19
12 Months 0.00 0.00
24 Months 0.07 0.37
No subjects had a positive score on any of the AIMS ratings at baseline.
Seven subjects (12.3%) developed tardive dyskinesia according to the Schooler
and Kane criteria within the 12-month follow-up period (see Table 13.14).
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Table 13.14
Details of the seven patients who developed TD in the first 12 months
F Probable o 2*o o
F Persistent 3o 3 8
F Persistent o 4 3 4
M Probable o 2*o o
M Persistent o 3 35
M Probable o o 2*o
* These ratings were reconfirmed within 1 week
** No subjects developed involuntary movements before 6 month rating.
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Table 13.15
Details of subjects who developed TD from 12 to 24 months
F
F
M
Persistent
Probable
Probable
Lips, jaw
Tongue
Lips, jaw
18 months
24 months
24 months
No subjects displayed signs of spontaneous dyskinesia at baseline, while 7
(12.3%) met Schooler and Kane criteria for persistent or probable TD at 12-
months follow-up. Details of these seven subjects are given in Table 13.14. At
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the end of 24 months, 11 subjects (19.3%) met criteria for persistent or probable
TO (LOeF data).
We compared the subjects with TO to the rest of the group, and found no
significant differences with regard to gender (Fisher exact p = .12), race (Fisher
exact p = .63), and duration of untreated psychosis (p = 0.5).
We did, however find differences between the groups with and without TO in
terms of the following variables:
Mean dose of haloperidol at 12 months: The mean dose of haloperidol at 12
months for subjects with TO by 12 months was 2.8mg/day (±1.64mg) versus
1.39mg/day (±O.69mg/day) for those without TO at 12 months (t = -3.13; df = 25;
P = 0.004).
If we consider the haloperidol dose at 12 months for subjects who developed TO
by 24 months, results are virtually identical (p = 0.004).
Age at inclusion into the study: The mean age of subjects who developed TO
within the first 12 months was 37.14 years (±9.23 years) versus 27.30 years
(±8.09 years) for those who did not develop TO ( t= -2.77; df = 30; P = 0.01). The
same comparison over 24 months yielded similar results (t =-2.96; df = 55; P =
0.005).
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Symptoms of EPS as measured on the Simpson-Angus Scale at 9 months:
The mean score on the SAS for subjects with TD by 12 months was 12.00 (±
1.83) versus 10.32 (±O.63) for subjects who did not develop TD by this time (t = -
3.97; df = 30; P = 0.0004). This difference remained significant at 24 months (p =
0.006).
Symptoms of EPS as measured on the Simpson-Angus Scale:
The mean score on the SAS for subjects with TD was 11.86 (±1.95) versus 10.20
(± 0.65) for subjects who did not develop TD by one year (t = -3.70; df = 30; P =
0.0009). This difference also remained sigrificant at 24 months (p = 0.01).
Mood symptoms as measured by the depression factor of the PANSS28:
The difference in mean score was only statistically significant at 6 months (i.e. in
the post-psychotic phase), with mean score for subjects who developed TD at
7.43 (± 3.21) versus 5.38 (± 1.69) for subjects who did not develop TD (t = -2.28;
df = 29; P = 0.03). We did not, however find any differences between subjects
who developed TD by either 12 or 24 months and those who did not in terms of
ratings on the Calgary Depression Rating Scale at any time.
In the initial statistical analysis, we did not find any significant differences
between the two groups in terms of symptom severity and changes in
psychopathology as rated on the PANSS, although percentage change in
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negative symptoms and PANSS total score did approach significance (see table
13.16)
Table 13.16
Changes in psychopatholgy over 12 months: Subjects with TO versus
subjects without TO
22.43 (±6.27) 0.55 30 0.584
38.14 (± 7.40) 1.86 30 0.072
95.04 (± 18.03) 84.86 (± 13.30) 1.39 30 0.176
12.57 (± 5.74) -1.04 30 0.308
15.56 (± 6.21) 19.29 (± 7.20) -1.36 30 0.185
25.96 (± 7.79) 25.29 (± 4.54) 0.22 30 0.829
51.76 (± 16.27) 57.14 (± 13.64) -0.80 30 0.431
59.12 (± 20.38) 44.76 (± 32.82) 1.43 30 0.162
31.42 (± 28.96) 6.93 (± 41.76) 1.79 30 0.083
1.35 (± 18.42) 30.97 (±20.02) 1.29 30 0.205
.46(±17.41) 30.27 (±21.66) 1.81 30 0.081
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Table 13.17
Changes in psychopatholgy over 24 months: Subjects with TO versus
subjects without TO
16.27 (±7.23) 0.45 54 0.656
23.91 (±7.05) 1.25 54 0.217
57.82 (±21.93) 50.82 (±16.19) 0.99 54 0.326
(±26.89) 55.96 (±21.74) -0.76 55 0.451
0.09 55 0.931
(±23.79) 39.26 (±18.66) 0.50 55 0.617
.36 (±23.06) 40.53 (±9.65) -0.42 55 0.676
In the second analysis, when we applied the proportional hazards method (Cox
regression) to investigate the effects of different predictor variables, we found the
following:
EPS ratings and mood symptoms were no longer significant predictors of risk for
TO. The following three variables were found to be significant predictors of risk
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for developing TO in the first year: age at inclusion, percentage change in
negative symptoms and dose of medication at 12 months.
Table 13.18
Significant risk factors for TO by 12 months (Cox Regression Analysis)
-0.035
1.289
-0.067 - 0.004
0.236 - 2.341
0.016
0.537
-2.199
2.399
0.028*
0.016*
*Significance at 0.05 level
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Figure 13.11
Percentage change in negative symptoms over 12 months
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We also compared the group of subjects who developed TO within the first 12
months to those who developed TO later. Although the numbers are very small,
there are some interesting trends evident:
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Table 13.19
Comparing subjects who developed TO within 12 months to those who
developed TO between months 12 and 24
5.25(±37.77} 49.22(±19.57} -2.14 9 0.061
35.16(±15.39} 46.44(±24.05) -0.96 9 0.362
33.58(±17.33} 52.70(±19.41) -1.70 9 0.125
Serious adverse events
We encountered only one adverse event that was rated as serious. This was a
19-year old female subject on phase I of the study who committed suicide.
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This subject was bom on 18-3-1979 and was included in the study on 6-01-2000
after a very brief period of psychosis. The subject had had a sudden onset of
psychosis with no noticeable prodrome.
She had no previous history of severe medical or psychiatric illness. She had no
family history of psychiatric illness, although her mother suffered epilepsy.
At baseline, she was rated as "Markedly III",with prominent paranoid delusions
and auditory hallucinations. Her initial diagnosis was noted as Schizophreniform
Disorder. Her medical work-up was unremarkable. What is notable is that she
also had a rating of 6 on the Calgary Depression Rating Scale at baseline.
On inclusion into the study she had already been on antipsychotic medication for
three days, with the result that she had signs of EPS, with a Simpson-Angus
Score of 23. There were, however, no signs of akathisia or dyskinesia present.
She responded very well to 1mg of haloperidol and was already rated as "much
improved" after one week. At visit 4/week 4 she was rated as apsychotic.
She was compliant on medication and attended follow-up regularly. She never
displayed any symptoms or signs of mood disturbance again.
Her last consultation was on 31-3-2000. At this time, she had been on the study
for 3 months and was again rated apsychotic. No mention is made in the notes or
any of the rating scales of any mood disturbance. At this consultation, her
medication dose was reduced to 0.5 mg per day. This was due to the fact that
she complained of sedation and stiffness. Her Simpson-Angus Rating Scale
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Score at the time was 13. There were no signs of either akathisia or dyskinesia
present.
The subject committed suicide on 2-06-2000 by taking an overdose of oral anti-
asthma medication (her mother's medication). Her mother did not report any
exacerbation in her psychosis or any obvious mood disturbance in the time
before the incident.
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Chapter 14
Results: Phase II
Forty subjects were included in the double-blind phase of the study, 20 subjects
in each treatment arm.
To evaluate the effect of randomization, we compared the two treatment groups
at baseline in terms of a number of variables. We found no statistically significant
differences between the two groups in any of the variables tested. Results are
presented below in table 14.1.
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Table 14.1
Comparison of two treatment groups (2mg/day vs 8mg/day) at baseline
a M = Male; F = Female
bM = Mixed; W = White; B = Black
c E = Ever Married; N = Never Married
d Fisher's exact test, two tailed
17: 2: 1 14: 2: 4 2.1 0.35
1 : 17 5: 13 0.18d
26.8 (±7.3) 28.9 (±8.1) 0.8; 34 0.42
27.0 (±5.7) 27.3 (±3.9) -0.19; 38 0.85
25.6 (±10.0) 23.9 (±6.4) 0.64; 38 0.53
47.6 (±9.5) 44.6 (±8.2) 1.05; 38 0.30
100.1 (±19.3) 95.7 (±13.0) 0.84; 3.0 0.41
10.5 (±1.8) 10.1 (±O.3) 0.86; 38 0.39
5.4 (±O.9) 5.2 (±O.7) 0.80; 38 0.43
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Of the 40 subjects included at baseline, 11 (27.5%) did not complete the full six
weeks of the study.
Of the 11 subjects who did not complete the study, 3 were in the low dose (2mg
per day) group, whereas 8 were in the standard dose (8mg per day) group. The
numeric difference between the two treatment groups did not, however reach
statistical significance (p = 0.08, Fisher's exact test, two-tailed).
When we considered the reasons for subjects not completing the study, the
following was found:
Six subjects were withdrawn due to EPS. All of these subjects were from the 8mg
haloperidd group. This means that 33.3% of subjects in the 8mg per day group
did not complete 6 weeks of treatment due to side effects. The difference in
withdrawal rates due to EPS was statistically significant (p = 0.02, Fisher's exact
test, two-tailed).
Three subjects were withdrawn due to poor response. Two of these subjects
were in the 8mg per day group and one in the 2mg per day group.
One subject withdrew consent shortly after baseline evaluation based on
religious grounds. He had been randomised to the 2 mg per day group.
One subject in the 2mg per day group failed to return from weekend leave after
week 4 evaluation.
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Table 14.2
Phase II: Subjects withdrawn from study
8mg 3 EPS
8mg 5 EPS
2mg 0 Consent
8mg 1 EPS
8mg 2 EPS
8mg 4 Poor response
2mg 4 Lost
8mg 5 EPS
8mg 1 Poor response
2mg 5 Poor response
In phase II of the study, there were no gender differences in dropout rates (chi-
square = .19; P = 0.67)
There were also no significant gender differences found in the following variables
(all LOCF data):
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Percentage change in PANSS Total Score and all subscale scores.
Remission rates.
EPS (as measured on the Simpson-Angus Scale or the ESRS).
Psychopathology
Table 14.3
Psychopathology Scores in Phase II
25.6 (±10.0) 23.9 (±6.4) 20.9 (±9.6) 20.3 (±10.8) 21.5 (±8.5)
47.6 (±9.5) 44.6 (±8.2) 36.4 (±17.3) 34.6 (±12.9) 38.1
(±20.9)
97.9
(±16.4)
100.1
(±19.3)
95.7 (±12.8) 74.2 (±30.9) 72.3 (±29.8) 76.1
(±32.6)
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Table 14.4
Percentage changes in psychopathology from baseline to endpoint
15.2 (±31.4) 21.8 (±31.0) 8.9 (±31.3)
20.1 (±38.4) 27.2 (±22.9) 13.4 (±48.6)
24.7 (±29.1) 28.9 (±23.9) 20.7 (±33.4)
PANSS Total Score
Although there was a numerical difference in improvement in PANSS Total
Score, this was not statistically significant at any evaluation point. Data is
presented below in table 14.5 and figure 14.1.
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Table 14.5
Percentage change in PANSS Total score over 6 weeks (LOCF)
9.8 (±16.8)
19.5 (±21.2)
22.3 (±22.3)
28.9 (±23.9) 20.7 (±33.4)
1.8
0.9
0.7
0.9
37 0.078
37 0.390
37 0.460
37 0.389
Figure 14.1
Percentage Improvement in PANSS Total Score
over 6 weeks (LOCF)
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PANSS Positive Subsca/e
Percentage improvement for the two groups was similar throughout. Data (all
LOeF) are presented below in table 14.6 and figure 14.2.
Table 14.6
Percentage change in PANSS Positive Subscale score over 6 weeks (LOeF)
24.9 (±19.9) 18.8 (±18.2)
32.1 (±26.2) 30.6 (±23.2)
33.7 (±27.4) 35.0 (±25.3)
36.0 (±27.6) 38.6 (±26.8)
1.0
0.2
-0.2
-0.3
37 0.32
37 0.86
37 0.88
37 0.77
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Figure 14.2
Percentage improvement in PANSS Positive Subscale over
6 weeks (LOeF)
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PANSS Negative Subscale
There was a large numerical difference in PANSS negative symptom subscale
scores throughout, although this only reached statistical significance at week 2.
The data (all LOeF) are presented below in table 14.7 and also in figure 14.3.
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Table 14.7
Percentage change in PANSS Negative Subscale score over 6 weeks
17.2(±22.6) -3.8 (±26.1)
18.1 (±29.2) 4.3 (±27.2)
20.4 (±29.8) 6.9 (±27.8)
21.8 (±31.0) 8.9 (±31.3)
2.7
1.7
1.5
1.3
37 0.01*
37 0.10
37 0.15
37 0.20
*Significance at the 0.05 level
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Figure 14.3
Percentage improvement in PANSS Negative Score over 6
weeks (LOeF)
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PANSS General Psychopathology Subscale
Once again, there was a large numerical difference between the two groups.
However, this did not reach statistical significance at any point. Results are
presented in table 14.8 and figure 14.4.
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Table 14.8
Percentage improvement in PANSS General Psychopathology Subscale
over 6 weeks (LOeF)
17.9 (±18.6) 9.4 (±18.5)
24.7 (±20.5) 17.6 (±25.0)
27.4 (±23.1) 19.8 (±25.9)
27.2 (±22.9) 13.4 (±48.6)
1.4
1.0
1.0
1.1
37 0.16
37 0.34
37 0.34
37 0.27
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Figure 14.4
Percentage Improvement in PANSS General
Psychopathology Score over 6 weeks (LOeF)
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Mood Symptoms
Mood symptoms were measured with the Calgary Depression Rating Scale.
There were no significant differences found between the two treatment groups.
Results are presented below in table 14.9 and figure 14.5.
Table 14.9
Mood Symptoms as rated on Calgary Depression Rating Scale over 6
weeks (LOCF)
1.6 (±4.1) 0.56 36 0.6
0.6 (±1.5) 1.4 (±3.3) -1.00 37 0.3
0.3 (±1.0) 1.3 (±3.0) -1.28 37 0.2
0.1 (±0.5) 1.3 (±3.0) -1.72 37 0.1
0.7 (±3.0) 1.2 (±3.0) -0.49 37 0.6
0.6 (±1.4) 1.2 (±3.0) -0.76 37 0.5
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Figure 14.5
Change in Score on Calgary Depression Rating
Scale over 6 weeks (LOCF)
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In this phase of the study, due to the relatively short duration, we did not find any
correlation with outcome in terms of PANSS negative symptoms as we did in the
first phase. However, there was a significant correlation between mood
symptoms at baseline (as measured on the Calgary Depression Scale) and the
duration of hospitalization (see table 14.10 and figure 14.6.)
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Table 14.10
Correlation between depressive symptoms at baseline and duration of
hospitalization
*Significance at the 0.05 level
Figure 14.6
Correlation between mood symptoms at baseline and duration of
hospitalisation
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Clinical Global Impression
Ratings over six weeks for the two groups on the Clinical Global Impression
Scale are presented below in table 14.11.
Table 14.11
Changes in Clinical Global Impression (CGI) Rating over 6 weeks
4.8 (±1.3) 4.8 (±1.0) -0.0 37 0.983
4.3 (±1.5) 4.4 (±1.3) -0.2 37 0.850
4.0 (±1.8) 3.8 (±1.4) 0.3 37 0.771
3.8 (±1.7) 3.6 (±1.5) 0.4 37 0.718
3.7 (±1.6) 3.7 (±1.5) 0.2 37 0.863
3.5 (±1.7) 3.3 (±1.7) 0.2 37 0.822
157
Stellenbosch University http://scholar.sun.ac.za
Side effect Ratings
As stated in the "Methods" section, subjects were evaluated for EPS with a
variety of instruments. These included the ESRS, Simpson-Angus Rating Scale,
AIMS and Barnes Akathisia Rating Scale.
Global Assessment of Side effects
This was rated with the total score (Items 1- 55) of the ESRS. Results are
presented below in table 14. 12 and figure 14.7.
Table 14.12
Changes in ESRS Total Scores over 6 Weeks (LOCF)
6.6 (±13.6) 8.9 (±19.3) -0.4 37 0.668
5.9 (±12.8) 21.6 (±27.2) -2.3 37 0.028*
7.2 (±13.6) 19.3(±20.5) -2.2 37 0.037*
6.2 (±8.3) 21.5 (±22.6) -2.8 37 0.008*
6.3 (±8.3) 22.6 (±23.7) -2.8 37 0.007*
8.4 (±11.0) 22.5 (±23.8) -2.4 37 0.024*
*Significance at the 0.05 level
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Figure 14.7
Change in ESRS Total Score over 6 Weeks (LOCF)
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Parkinsonism
Parkinsonism was evaluated using two different scales. Firstly, we used the
ESRS.
Simpson-Angus Rating Scale and secondly, the parkinsonism subsection of the
159
Stellenbosch University http://scholar.sun.ac.za
Simpson-Angus Rating Scale
There were clear, statistically significant differences between the two groups from
week two onwards. Data is presented below in table 14.13 and figure 14.8.
Table 14.13
Ratings on Simpson-Angus Scale for the two groups over 6 weeks (LOeF)
13.1 (±6.6) 13.7 (±6.7) -0.3 36 0.767
12.6 (±5.6) 17.8 (±8.5) -2.3 37 0.030*
13.2 (±6.0) 17.8 (±7.6) -2.1 37 0.046*
12.5 (±3.2) 18.5 (±8.0) -3.1 37 0.004*
12.3 (±3.1) 19.1 (±8.8) -3.2 37 0.003*
13.1 (± 3.9) 19.1 (±8.8) -2.7 37 0.010*
*Significance at the 0.05 level.
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Figure 14.8
Score on Simpson-Angus Scale over 6 Weeks
(LOeF)
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Parkinsonism subsection of the ESRS
This subsection consists of items 13 - 30 of the ESRS. Our findings on this scale
were very similar to those on the Simpson-Angus Scale. Results are presented
below in table 14.14 and figure 14.9.
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Table 14.14
Ratings on Parkinsonism subsection of the ESRS for the two groups over 6
weeks (LOeF)
5.4 (±11.3) 7.0 (±14.7) -0.4 37 0.709
4.6 (±10.2) 15.6 (±17 .5) -2.4 37 0.023*
6.0 (±11.1) 15.7 (±16.0) -2.2 37 0.035*
5.7 (±7.1) 17.9 (±17.2) -2.9 37 0.007*
5.8 (±7.4) 18.5 (±18.2) -2.8 37 0.008*
7.3 (±8.7) 18.6 (±18.2) -2.5 37 0.019*
*Significance at the 0.05 level.
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Figure 14.9
Score on ESRS Parkinsonism Subscale over 6
weeks
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What is also important, however, is that, for both treatment groups, there was a
statistically significant change in ESRS rating from baseline to endpoint:
2mg Group: t = -2.9; df = 18; P = 0.009 (paired t-test)
8mg Group: t = -4.7; df =19; P = 0.0002 (paired t-test)
Dystonia
Acute dystonia was measured by means of items 31 - 39 of the ESRS. There
were 8 subjects who developed dystonic reactions at some point during the study
(after baseline). Of these 8 subjects, 2 were in the 2mg haloperidol group and 6
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were in the 8mg haloperidol group. This was not a statistically significant
difference (p = 0.13; Fisher's exact test, two-tailed).
Once again, however, it is important to notice that one third of subjects in the
8mg per day group had a dystonic reaction.
As a result of the short duration of the study, there were no cases of tardive
dystonia.
Tardive Dyskinesia
There was one subject who clearly had abnormal movements at baseline and a
score of 7 on the AIMS. These abnormal movements persisted throughout the 6
weeks of the study. One other subject scored 1 on the AIMS at baseline. This
second subject did not, however, display any signs of abnormal involuntary
movements after the baseline evaluation.
At the end of the study period, two more subjects had some signs of abnormal
movements: One subject developed abnormal involuntary movements from week
4. These persisted for the next three evaluations, but achieved a score of only 2
on the AIMS.
The other subject had a score of 8 on the AIMS at the last evaluation (week 6),
but no signs of abnormal movements at any of the other evaluations. Both of
these subjects were in the 8mg haloperidol group.
There were no statistically significant differences found between the two groups
in terms of AIMS score (t = 0.04; df = 37; P = 0.97)
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Akathisia
Eleven subjects (28%) were judged to have developed akathisia at some point
during the study. Of these subjects, 3 were in the 2mg per day group and 8 were
in the 8mg per day group. This numerical difference did not reach statistical
significance (p = 0.16, Fisher's exact test, two-tailed). However, it should be
noted that 40% of subjects in the 8mg per day group developed akathisia.
There was also a significant difference in risk for dystonia between the group of
subjects who developed akathisia and those who did not (p = 0.028, Fisher's
exact test, two-tailed).
Table 14.15
Risk of dystonia in subjects who developed akathisia
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Concomitant medications
In this phase of the study, concomitant medications were monitored closely. All
concomitant medications, as well as the cumulative weekly dose of each, were
recorded at each visit for the preceding week.
Four medications used are discussed here: Lorazepam, orphenadrine,
biperidine and fluoxetine.
Lorazepam
The mean dose of lorazepam used did not differ significantly between the two
groups. Mean doses for the two groups are presented below in table 14.16.
Table 14.16
Mean doses of lorazepam used for the two groups over 6 weeks (LOCF)
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Orphenadrine
There was a significant difference in the mean total dose of orphendrine used
between the two groups. Mean total doses over 6 weeks are presented below in
table 14.17.
Table 14.17
Mean total doses of orphenadrine used over 6 weeks (LOeF)
Biperiden
Three subjects had to have injections with biperiden for the treatment of acute
dystonia. In two of the three cases, the incident happened within the first week
and in the third case it happened in the second week of double-blind treatment.
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Fluoxetine
Four subjects (10%) received concomitant treatment with f1uoxetine during the 6
weeks. Of these, 2 were male and two female. Three of the subjects were from
the low-dose group and one from the 8 mg group. This was not statistically
significant (p = 0.9, Fisher's exact test, two-tailed).
There were no differences in terms of ratings of psychopathology, side effects or
outcome between the group who took f1uoxetine and those who did not.
Prolactin
As a result of problems with the laboratory and collection of samples, we were
able to collect reliable information on only a limited number of subjects. However,
we still found a statistically significant change in prolactin levels for the whole
group from baseline to endpoint, as well as for the 8mg group, but not for the
2mg group (see table 14.18.)
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Table 14.18
Change in mean prolactin level for whole sample
14.1 (±10.1) 15.5 (±8.4) -0.38 9 0.70
14.1 (±9.5) 51.4 (±34.8) -3.49 10 0.006*
*Significance at 0.05 level
As can be expected, this was also reflected in a statistically significant difference
between the low dose and standard dose groups in prolactin levels at endpoint
as well as the change in prolactin levels from baseline to endpoint:
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Table 14.19
Mean prolactin levels at endpoint
Table 14.20
Change in mean prolactin levels between baseline and endpoint
Table 14.21
Prolactin levels at endpoint for male subjects
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Table 14.22
Prolactin levels at endpoint for female subjects
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Chapter 15
Discussion
General
This is, to our knowledge, the largest study to date of first episodes of psychosis
in a South African population. It offers unique information on the demographics,
clinical presentation, response to treatment and outcome in a population that is
markedly different from North American and European populations. There is
good reason to believe that patients from different parts of the globe may present
and respond differently to treatment", however this has not been studied
extensively and more studies are needed to provide comparable data. Our study
confirmed many of the findings of previous first-episode studies, while also
presenting data that is new.
Gender
There have been suggestions in the literature before that schizophrenia may be a
less severe disorder in women than in men59;100. Our study provided mixed
findings in this area:
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Female subjects in our study were considerably older than male subjects at
inclusion. Other studies have also found earlier onset in males, with later peaks
for females227. Females from our group were more likely to be married and also
more likely to have produced offspring. Our findings in this regard are similar to
that of studies from other parts of the world, which showed women to have higher
overall premorbid functioning, more likely to be in stable relationships and more
likely to be parents 228.
It is somewhat questionable though, if in a fairly traditional society like South
Africa, the increased likelihood of being married and having produced offspring
are, in fact indicators of higher social functioning. Women often have limited
rights in society and are more likely to be passive participants in courtship,
marriage and sexual relationships. Marriage could therefore not be considered as
a reliable measure of social functioning. The fact that the women were older at
inclusion than the men could also confound other variables, such as marriage
and fertility. In contrast to the finding that women were older than men at
inclusion, we did not find any significant difference in duration of untreated
psychosis, suggesting that the onset for female subjects was in fact later and not
a result of delayed help-seeking.
On most other demographic measures as well as measures of outcome that we
had available, we did not find any difference between the genders. In fact, we
were surprised that there was no difference in the level of schooling between
male and female subjects.
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The one very significant difference between the genders that remains difficult to
explain is the dropout rate in filase I. Fourteen female subjects dropped out of
the study in the first year alone, compared to only 4 male subjects. The
difference remained significant at two years. The fact that women have a later
onset of illness and are more likely to have a family of their own seems to be the
most likely cause. Factors such as pressure to return to work and caring for the
family - in particular the children - seemed to have played a major role here. In
the shorter, phase II study, we did not find a similar problem with drop-out rates.
Unlike other studies, we did not find poorer outcome for male subjects on clinical
measures. This finding may have been confounded to some extent by the high
initial drop-out rate for female patients in phase I, as the LOCF data for females
may therefore reflect more severe psychopathology at endpoint. However, in the
phase II study, where there were no gender differences of note in drop-out rates,
outcomes were also similar in terms of clinical measures.
Ethnicity
The ethnic distribution of our study sample does not fully reflect the racial
compilation of the population ei the Western Cape, but rather that of the
catchment area of Stikland Hospital. The vast majority of patients who make use
of the hospital facilities are of mixed racial origin (African-Caucasian). There is
now considerable evidence from the literature that ethnicity may playa role in
presentation, treatment response and outcome of schizophrenia229;23o. Therefore,
some of our results, particularly those pertaining to dose of medication and
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tardive dyskinesia, should be considered in the light of these ear1ierfindings.
Although significant in the South African and perhaps African context, results
might therefore not necessarily be valid in other population groups.
Unfortunately, the numbers of subjects in this study were not large enough to
compare ethnic groups in terms of presentation and treatment response.
Employment history
Subjects with first-episode psychosis are often dysfunctional for many years
before the first, florid psychotic episode231. This is usually reflected in poor
scholastic and work performance. Results from our study are somewhat difficult
to interpret, as South Africa is a society with a high rate of unemployment. We
did not do a survey of a similar control group to determine whether the rate of
unemployment in our study group was statistically higher than that of the general
population in our area. Nonetheless, the finding that more than 60% of subjects
were unemployed and that only 15% were fully employed, seems much higher
than the norm. Furthermore, only 50% of subjects were ever fully employed
during their lifetime. This again suggests a high level of impairment from an early
age.
It is true that United Nations resolution 46/119 states that every person with a
mental illness has the right to live and work in the community. Sadly, this remains
an unfulfilled ideal. What is positive in our study however was the finding that the
majority of subjects had very close and regular contact with their families and
seemed to live in family homes. Less than 10% of subjects were homeless, lived
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in a shelter or a squatter camp. This may support the earlier finding that subjects
with mental illness in developing countries seem to have better social support
structures than their counterparts in the developed world232.
Perhaps one of the greatest frustrations we encountered during this study was
the relatively poor quality of information obtained on personal history. Because
record keeping in South Africa has been so poor in the past, there were no
official records to verify information against.
Duration of untreated psychosis
Most studies of first episodes of psychosis across the world have shown a
marked treatment delay, that is the time from onset of frank psychosis, up to first
treatment is instituted46;48;95. This delay is known as the duration of untreated
psychosis (DUP). We found a very similar pattem in our population, where
subjects were, on average, psychotic for about one year before they accessed
mental health services. What is interesting to note is that the DUP in our study
was not very different from that of studies in the first world95•
Some authors have suggested that the DUP is associated with outcome on a
variety of measures46;48;68, although others have disputed this claim72;73. In this
study, we did not find any correlation between the DUP and measures of
psychopathology at baseline, doses of medication used or clinical measures of
outcome over the short term. However, we did find that DUP correlated
significantly with the improvement in PANSS Negative Scale over the latter part
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of phase I. From the data presented in table 12.9, it seems that the correlation
becomes progressively more pronounced over time. Also, we found a significant
correlation between DUP and improvement in PANSS Total Score. This
correlation was less robust though than the correlation with the Negative Scale,
but still significant at 24 months.
It should be remembered that evaluation of the DUP is a particularly difficult task.
We did not use any specific rating scales for DUP in this study, but rather used
information obtained form patients and their carers to come to a consensus
agreement on the DUP. It may therefore be that our data is less reliable in this
regard than studies that used specific rating scales for this purpose.
Phase I
Measures of efficacy
Our study supports and extends previous work indicating that low-dose
haloperidol is effective and well tolerated in patients with first-episode
schizophrenia61:62:90233.The degree of efficacy is difficult to ascertain from phase
I, as a comparator drug was not used here. However, compared to other studies
in first-episode schizophrenia, the effect appears to be at least as good. Thus,
the study by Emsley et al90comparing risperidone and haloperidol in first-episode
psychotic patients reported a mean reduction in PANSS total score of 30.9 for
risperidone (mean dose at endpoint 6.1mg/day) and 29.3 for haloperidol (mean
dose at endpoint 5.6mg/day) after a 6-week treatment period. At 6 weeks the
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PANSS total score reduction in our study was 28.5. In the study by Lieberman et
al234comparing haloperidol and olanzapine, the response was somewhat poorer.
For olanzapine (mean dose 9.1mg/day) and haloperidol (mean dose 4.4mg/day)
the reductions in PANSS total score over 12 weeks were 18.63 and 16.97,
respectively. In our study the PANSS total score reduction was 38.0 at 12 weeks,
40.3 at 12 months and 36.4 at 24 months.
The improvement in negative symptoms over the course of the study is also
important. It could be that low doses of haloperidol are less likely to cause the
secondary negative symptoms that are often associated with the use of standard
doses of traditional antipsychotics, while at the same time successfully treating
negative symptoms that are secondary to positive symptoms and possibly even
"core" negative symptoms33:235.
From this study it seems that the majority of the improvement occurs within the
first 6 months of treatment with haloperidol, after which improvement seems to
level out, with little change over the following 18 months. It would be of great
interest to see how the second generation antipsychotics perform over a similarly
long period of treatment, as differences in effect size may become apparent only
later in treatment.
The importance of maintaining doses at low levels for long enough to allow for
maximum response has been emphasized before88, and it has even been
suggested that it may take several months for maximum response to develop'?'.
In their study of low-dose haloperidol in first-episode psychosis, Zhang-Wong et
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al 62 commented that, had they been able to maintain doses at lower levels for
more than seven days, more patients might have responded at low doses. Our
study supports this notion. In fact, an important aspect of our phase I study was
that investigators were strongly discouraged from increasing the doses of
medication for at least a month, thereby allowing time for the effect of the very
low dose of medication to set in.
Mood symptoms
As discussed earlier, symptoms of depression are common in patients with
schizophrenia. Depending on criteria applied and samples studied, depressive
symptoms have been reported to be present in between 7% and 70% of patients
with schizophrenia 34, Vllitha modal prevalence rate of 25% 35.
Previously thought to be uncommon in the acute phase of the illness, it was
proposed that the florid symptoms of psychosis might mask depressive
symptoms that persist, and are later 'revealed' when the psychosis is
successfully treated 236. However, it is now recognized that depressive symptoms
are a key feature of the acute psychotic episode, and that the majority of these
symptoms resolve with antipsychotic treatrnenr'". There are various
explanations for depressive symptoms in schizophrenia, such as a subjective
reaction to the illness and its accompanying adverse life events238, substance
abuse239, co-morbid major depressive disorder or anxiety disorders, and
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neuroleptic-induced dysphoria24o. In the stress-diathesis context, depressive
symptoms may themselves constitute a stressor that triggers a psychotic
episode". It has also been suggested that the depressive symptoms
experienced in acute psychosis are a core feature of the illness itself 237.
There have been conflicting reports regarding the relationship of depressive
symptoms to treatment outcome. However, it would appear that their presence in
the acute phase of the illness might be associated with a favourable outcome 36,
while persistent depressive symptoms appear to be negative prognostic
indicators37-39.
In keeping with previous studies, we found that depressive symptoms are
common in first-episode psychosis (42% at baseline in this sample).
This once again does not support the notion that depression is only 'revealed'
once the psychosis remits236, as depressive symptoms were prominent at the
outset and diminished substantially as the psychotic symptoms improved. Also,
our findings argue against the likelihood that depressive symptoms in
schizophrenia are misdiagnosed negative syrnptomsê" - in which case a
significant association between negative and depressive symptoms would have
been expected. Finally, the baseline depressive symptoms identified in our
sample are unlikely to be related to any pharmacological treatment or it's side
effects242, as the majority of subjects were medication naïve on entry to the
study.
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The lack of a significant association between PANSS depression factor scores
and positive symptoms in our study was surprising, given the fact that such an
association has often been reported237;243-245. The reasons for our failure to
demonstrate such an association was not immediately apparent, as these
symptoms are thought to co-occur in acute psychosis, and simultaneously
improve with successful antipsychotic therapy'". However, when we analyzed
the data from the Calgary Depression Rating Scale (CDRS), we found not only a
more robust association with improvement in PANSS Negative Score than we did
with the PANSS depression factor, but also found an association with
improvement in PANSS Positive Score, General Psychopathology Score and
PANSS Total Score.
These findings may be interpreted in a number of ways. Firstly, recent work
indicates that depressive symptoms may also emerge independent of positive
symptoms. In a 12-month prospective study of 105 subjects with schizophrenia,
two course patterns of depressive symptoms were identified - those following the
same course as positive symptoms during psychotic episodes, and those
emerging de novo without a change in positive symptoms". Another, more likely
interpretation of the findings would however be that the CDRS provides a more
sensitive measurement of depressive symptoms in psychotic patients, having
been designed specifically for this purpose. Findings with the PANSS
Depression factor should therefore be interpreted with great care and should, in
our opinion be verified where possible by comparing it to data using the CDRS.
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Both sets of analysis (PANSS Depression Factor and Calgary Depression Scale)
identified a previously unreported inverse relationship between acute depressive
symptoms and persistent negative symptoms - i.e. higher acute depression
scores being predictive of fewer negative symptoms later on (or as it is stated in
the results, a greater percentage reduction in PANSS Negative Symptom score).
Thus, our findings suggest that the presence of depressive symptoms in the
acute psychotic phase of the illness is a favourable prognostic indicator, given
the well-established association between negative symptoms and poor overall
outcome51;246. In a recent studj47 investigating relationships between
depression and psychotic symptoms over the course of the illness, it was found
that depressive symptoms in the acute phase were associated with positive
symptoms only. However, depressive symptoms in the stable phase, in addition
to being associated with positive symptoms, showed a positive correlation with
negative symptoms. This finding, taken together with the results of our study,
provides compelling evidence that symptoms of depression in the acute phase
predict favourable outcome, while symptoms of depression that persist or
emerge after the acute phase are predictive of poor outcome.
Our findings are in keeping with the theory of symptom dimensions in psychosis
as proposed by Shergill et a1248.According to these authors, a clear dichotomy
between schizophrenia and mood disorders does not exist. Rather, the aetiology
of psychosis can be explained by the interactive effects of two major types of risk
factors: first, those conferring neurodevelopmental impairment and second, a
genetic predisposition to react to adverse life events by developing psychotic
symptoms. Mood symptoms tend to be more prominent at the life events/genetic
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predisposition end of the spectrum, and therefore, are presumably associated
with a more favourable outcome. Conversely, negative symptoms are associated
with neurodevelopmental impairment, and therefore poorer outcome. Our data
support this inverse relation between depressive symptoms and negative
symptoms and provide a possible explanation for the previously reported positive
prognostic effect of depressive symptoms in acute psychosis.
Another aspect of these analyses is that the Calgary Depression Scale seems to
yield better correlations with outcome variables than the PANSS Depression
Factor score. This is interesting and suggests that the Calgary Depression Scale
should probably be the instrument of choice when evaluating the depression
symptoms of schizophrenia and schizophrenia-like psychoses, as it is the more
sensitive instrument of the two.
Measures of tolerability
Side-effect ratings
Phase I provides mixed results in terms of tolerability. The finding that there were
no significant differences on any of the rating scales for parkinsonism, akathisia
or dystonia over the study period compared to baseline suggests a more
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favourable EPS profile compared to even only slightly higher haloperidol
doses90;234 and seems to support PET studies 121;188;188;189 that suggest sufficient
D2-occupancy and antipsychotic efficacy with haloperidol doses as low as 2mg.
The incidence of TD in this sample, however is considerably higher than
expected. Considering that lower dosing strategies are reported to afford some
protection against TD 155, we would have anticipated a rate below the ±5% per
year of treatment reported with standard doses of conventional anti psychotics
144;145. Even disregarding the cases of 'possible' TD, the 12 month incidence of
'persistent' TD of 5.3% in the present sample is similar to that previously
reported, whereas the 24 months figure for 'persistent' TD at 15.8% is higher
than would be expected. Thus, while lower doses of conventional antipsychotics
have a low risk of inducing acute EPS62;188;225 , this does not appear to be
associated with a reduced risk for TD. Otherwise stated, patients do not escape
the neurotoxic effects of haloperidol even when exposed to low doses of the
agent. The results of this study therefore call into question earlier proposals by
ourselves225 and others 154 that haloperidol in low doses may be a reasonable
alternative to the atypical antipsychotics.
It is important to note that, while the dose of haloperidol at 12 months was a
significant indicator of the development of TD at both 12 and 24 months, the
dose of haloperidol at 24 months was not. The reason for this is simple: the
protocol allowed for a number of interventions when TD developed, such as
reducing the dose of medication or withdrawing the subjects from haloperidol.
Thus, subjects who developed TD in the early part of the study would have had
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significant interventions by 24 months, thereby making the haloperidol data at 24
months unreliable in terms of its relationship to TO.
The finding of a relationship between the onset of dyskinesia and a worsening in
negative symptoms, depressive symptoms and parkinsonism scores is of
interest. While an association between TO and negative symptoms is well
documented 26:249, their temporal relationship has not been described. Orofacial
TO in particular, has been linked with negative symptoms. It is of interest that all
of our TO subjects fell into this subsyndrome. We are not aware of a previously
reported association between depressive symptoms and TO. Whereas the
majority of depressive symptoms in schizophrenia occur in the acute phase, and
resolve as the psychosis remits237, there are patients with persistent depressive
symptoms or those emerging de novo 34 that appear to be associated with poor
social and vocational functioning38:39, increased risk of relapse238 and suicide. It
is these persistent, or emergent depressive symptoms that were associated with
TO in our sample.
Our study confirms that baseline clinical features are not significant predictors of
TO 145, and further suggests that the acute response to antipsychotic treatment is
similar in both TO and non-TO subjects. Some undefined event then appears to
trigger the onset of TO in certain individuals, with the simultaneous emergence of
negative and depressive symptoms, as well as features of parkinsonism. (It
needs to be remembered however, that mood, negative and parkinsonistic
symptoms are difficult to distinguish from one another, and may be
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misinterpreted on the assessment scales.) This phenomenoo could be explained
on the basis of a disease-related vulnerability to TO that is manifest with drug
exposure. It has been proposed that patients who are more severely ill and less
responsive to treatment have increased vulnerability to TO, either due to an
intrinsic aspect of the disease process, or due to greater antipsychotic drug
exposure!". However, the fact that TO patients did not differ from non-TO
patients in terms of baseline psychopathology and acute treatment response
demonstrates against this. Also, TO patients did not have more persistent
psychotic symptoms, as would be expected in a more severe form of
schizophrenia. It would appear rather that TO emerges together with negative,
depressive and parkinsonism symptoms. While exposure to antipsychotic
treatment may be a necessary factor, the risk may not necessarily be dose-
related. An alternative explanation for the reported association between dose
and risk of TO 144 145;155 is that these negative and depressive symptoms are
interpreted by clinicians as a deterioration in the patient's condition, with resultant
increasing of the antipsychotic dose. This would explain our finding of a
significant association between TO and drug dose only at 12 months, and not at
the onset of TO. Furthermore, the increase in parkinsonism scores that we found
could also be a consequence of increased antipsychotic dose.
As was the case in a number of previous studies, we found an association
between age and TO development 141;142;144;250. This was somewhat surprising,
given the youthful age and limited age range of our sample, indicating that age
as an independent risk factor for TO is not limited to elderly samples. Our failure
to identify g~nder, race and acute EPS as risk factors for TO is in keeping with
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the findings in a similar cohort of first-episode schizophrenia patients 145.
However, the incidence of acute EPS was extremely low in our sample, so that
comparisons were difficult.
TO is likely to remain a focus of attention in the management of psychosis for a
long time. The failure of low-dose haloperidol to reduce the risk of TO is
disappointing, and argues strongly against its use as first-line treatment in
psychosis if a choice of agents is available.
Phase II
This part of the study had a traditional double-blind design, with both the
advantages and disadvantages of this type of study.
Comparing the two groups at baseline
The two treatment groups were similar at baseline in terms of both demographic
variables as well as measures of psychopathology. Both groups of subjects were
quite ill at admission, with PANSS Total Score around 100 and CGI ratings of >5
(Severely ill) at baseline. This is so because the patients were almost exclusively
recruited from the acute, inpatient units at Stikland Hospital. By definition
therefore, these patients were at the more extreme end of the spectrum in terms
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of severity of illness. It could be argued that this is not a representative sample,
as many patients with a first episode of psychosis may not need to be admitted
and may have symptoms that are more subtle. However, for the purpose of this
study, we believe that this situation has actually enhanced the generalizability of
the study - the fact that the very low dose of medication was effective in even the
most severe cases most likely indicates that it will be effective over the entire
spectrum of severity.
Measures of efficacy
We compared the two groups of subjects, namely those on the low dose of
haloperidol (2mg per day) and those on standard dose (8mg per day), on a
variety of measures of outcome.
The two doses of haloperidol were both effective in treating the global symptoms
of psychosis, as measured by the PANSS Total Score, in a majority of patients.
This is important for a number of reasons, but most important of all, it shows that
the low dose strategy is at least as effective as the so-called standard dose in the
first weeks of treatment.
When we consider the effects of the two treatments on positive symptoms, we
again see that there was no difference between the two groups. It is also of
interest to note that, even at an early stage of treatment, for instance in the first
week of treatment, subjects on lower doses responded as well as those on the
higher dose.
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But it is in the effect on negative symptoms that we see the most marked
differences. Unfortunately, the relatively small number of patients in the study
limited the power of the statistical analysis. Even so, there were large numerical
differences in the effect on negative symptoms for the duration of the study. This
reached statistical significance at week 2, but even at the end of the study, there
was still a 13% difference in effect between the two groups. It has often been
suggested that first-generation antipsychotics have a very limited treatment effect
on negative symptoms and may, in fact, exacerbate these symptoms. This study
gives some indication of why this is so - in many studies comparing second-
generation antipsychotics to haloperidol, the mean doses of haloperidol were
considerably higher than 8mg per day153;204. If the difference between 2mg and
8mg is this marked, one can imagine what the difference would be between
2mg/day and 15-20mg/day, a dose often used in comparator studies.
We did not find any difference between the two groups in terms of their effect on
the depressive symptoms associated with psychosis. The brief duration of this
part of the study also did not allow for the proper evaluation of the effect of
baseline mood symptoms on longer-term outcome as we did in Phase I.
However, an interesting finding that may support the findings on the effects of
baseline mood symptoms in Phase I, was an inverse correlation between
baseline depressive symptoms as measured on the Calgary Depression Scale
and the duration of hospitalization: the more depressive symptoms a subject
presented with at baseline, the shorter the time spent in hospital. This may be a
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further indicator of improved outcome for those patients with depressive
symptoms at baseline, albeit in an indirect way.
From the above, it is clear that haloperidol at 2mg per day is as effective in
treating the first episode of psychosis as 8mg per day. There are suggestions
here that the lower dose may, in fact, be more effective. This is particularly true
for the negative symptoms and the general psychopathology symptoms as
measured on the PANSS. We believe, as others have suggested before83, that
there is a therapeutic window effect with haloperidol, and that increasing doses
may not only be ineffective in increasing the treatment response, but may also
have a toxic effect and lead to poorer outcome in the long run.
Measures of tolerability
It should be kept in mind that even the so-called "standard dose" of haloperidol
used in this study was a conservative one, as doses over 10mg are
commonplace in general adult psychiatry. In fact, most recent guidelines suggest
does between 6 - 20mg per day176;251. As recently as the mid-1980's to mid-
1990's, subjects in the largest and perhaps most widely quoted first-episode
study were receiving doses of haloperidol and other medications in dose
equivalents that were much higher than 10mg per dal5.
The drop out-rate in this study was similar to that of other studies of double-blind
treatment over a six-week period90;204. Although the difference between the two
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treatment groups did not reach the statistically significant level of 0.05, there was
a clear numerical difference between the two groups, with 8 subjects in the 8mg
group failing to complete the study, whereas only 3 of the patients in the 2mg
group failed to complete.
When we consider the reasons for withdrawal, the difference between the two
groups is remarkable: 6 patients failed to complete the study due to EPS and all
6 were in the 8mg group. Despite earlier reports of doses of haloperidol below
10mg being tolerated well, this was certainly not the case in our study population.
If almost 30% of subjects on 8mg/day withdrew over the first six weeks due to
EPS, it is difficult to imagine that there would be an acceptable rate of
compliance over the long term, particularly as EPS have been shown to be the
principal cause of non-compuance'F.
The ratings of side-effects provide even more evidence in support of the poor
tolerability of "standard" doses of haloperidol: on evaluation of overall scores of
EPS (such as the ESRS global score) as well as on the scales that measure
parkinsonism (ESRS parkinsonism subsection as well as the Simpson-Angus
rating scale), there were significant differences between the two groups from the
second week up to the end of the study.
It should furthermore be noted that, despite the fact that the 2mg dose was
much better tolerated than the 8 mg dose, even this very low dose caused some
side-effects and there was a statistically significant change in parkinsonism from
baseline. It is therefore different from the phase I study, where we did not find
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statistically significant differences in EPS between baseline and the later
evaluations. This illustrates one of the shortcomings of the fixed- dose, double-
blind design: when researching the effects of a compound with a very narrow
therapeutic index such as haloperidol, this study design does not allow for "fine-
tuning" of doses, as we were able to do in the Phase I design (and which one
would certainly do in the clinical situation). Indeed, although it was our aim to use
the dose from the Phase I study to evaluate against the standard dose, it leaves
us with the interesting possibility that there may be a large enough difference
between 1.7mg/day (the mean dose from the Phase I study) and 2mg/day (the
dose we "rounded it off' to) in terms of receptor occupancy to "overshoot" the
70% 02 occupancy zone for antipsychotic effect as suggested by Kapur et
aI109;188;189 and already exceed the EPS-causing 80% occupancy level, at least in
a significant number of individuals. This is even more thought provoking when we
consider the TO data from phase I - seemingly, doses below 2mg/day did not
cause TO, whereas a dose above 2mg/day did.
As with the dropout rates, we found that the numerical difference in incidence of
akathisia and dystonia did not translate into statistical significance. However, the
results of the study in this regard are still important and again raise a number of
issues:
a) More than 25% of patients in this study developed akathisia - an
otten-underrecognised phenomenon. A similar number (22.5%) developed
dystonic reactions atter initiation of treatment.
b) Forty percent (8/20) of patients in the 8mg group developed
akathisia and 30% in this group had dystonic reactions. In the case of 5
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subjects, the risk of akathisia and that of dystonia overlapped (i.e. the
patients who were at risk for akathisia, were also the ones who developed
dystonia)
c) Even at the 2mg dose, some patients developed akathisia.
d) Patients who developed akathisia, are at increased risk of having
dystonic reactions, and vice versa.
This data is of great importance to us, as akathisia has been shown to be not
only the single most common cause of non-compliance, but may in severe cases
lead to suicide. This most uncomfortable and distressing of side effects has been
described in graphic detail by Kendle,-252,after taking only 1mg of haloperidol.
Clinicians, unfortunately, remain poorly equipped to recognize this side effect,
often ignoring the patient's subjective experience of inner restlessness and
waiting for objective signs thereof. Similarly, clinicians (in particular the young
and inexperienced) may misinterpret dystonia as "manipulation" by the patient, to
get either medication or attention from staff.
As we expected, we did not find any significant indications of tardive dyskinesia
in this short-term study.
Concomitant medications
We were encouraged that subjects in the low-dose group did not need more
sedative medication (in the form of lorazepam) than those on the higher dose.
Indeed, the mean doses used over 6 weeks were virtually identical (see table
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14.16). This shows that the higher dose of medication is no more effective in
achieving even its misguided goal of increased sedation. It is indeed encouraging
to see that, despite the lowering of doses from those traditionally prescribed,
subjects used on average only about 1mg of lorazepam per day of the study.
The use of antiparkinsonian medication reiterates the poor tolerability of the
8mg/day dose. The patients in this group used between three and four times as
much orphenadrine as the 2mg/day group. Furthermore, despite the fact that
there were no restrictions placed on the use of antiparkinsonian medications and
the fact that the 8mg group used it in much larger quantities, this still did not
achieve the desired goal of preventing/treating EPS successfully, as reflected in
the data on these side-effects.
The data on the use of antidepressants in this group is too limited to make any
deductions from. The only clinically significant finding here was that, within the
first 6 weeks, 10% of the subjects became depressed enough to be treated with
antidepressants.
Although our data on prolactin levels were limited due to laboratory problems, the
data that we had did not show any significant increase in prolactin levels for the
2mg/day group, whereas the 8mg/day dose had a marked, significant effect on
the prolactin level. It can be postulated therefore that low doses of haloperidol
may hold a much-reduced risk of the potential long-term detrimental effects of
increased prolactin. As discussed in the section on prolactin in the introduction,
increased prolactin levels may cause a number of "down-stream" effects, some
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of which may be uncomfortable (sexual dysfunction), but also others such as
osteoporosis that may have severe medical implications. An interesting finding
here was that the low-dose treatment had a much more profound effect on the
prolactin levels of male subjects than on female subjects, whereas the higher
dose affected both sexes, but with a greater mean effect in female subjects.
It is clear then, that on all measures of outcome, the 2mg dose was at least as
effective as the 8mg dose. There are some indications of superiority for the low-
dose group in some aspects of efficacy, particularly in terms of the treatment of
negative symptoms. Whether this would be a sustained effect needs to be
evaluated in longer-term studies, although data from the phase I study seems to
suggest that there is a long-term effect. There can be little argument as to the
tolerability of the two treatments: in fact, we were surprised at how poorly the
8mg dose was tolerated and how high the dropout rates with this treatment were.
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Chapter 16
Limitations
Every study design has its limitations, and this one is no exception. We consider
the following to be the major shortcomings of this study:
1. Phase I did not have a comparator group and had an open-label,
algorithm based design. This may have lead to prejudice on the side of the
investigators.
2. Although the 97 patients that we recruited presents a large group in terms
of first episode studies, the power of the study would have been enhanced
had we been able to recruit even larger numbers.
3. There was no placebo group in the study. This could not be considered,
however, as it would have been an unethical practice to withhold
treatment from acutely ill patients.
4. Phase II ran over only 6 weeks. Longer study duration may have yielded
different results.
5. Also, it may be that our findings cannot be generalized to all ethnic
groups. Previous work suggests that patients of African descent may be
at particular risk for developing TD147, and we have reported significant
racial differences in treatment response to antipsychotics=", suggesting
that some groups may be more sensitive to the effects of these agents.
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The principal reason for using the 2 study designs was to try and reduce the
limitations of both kinds of study as far as possible. We believe that we have
achieved this to some extent, gathering both short-term and longer-term data.
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Chapter 17
Conclusion
"If somebody is hearing voices we dont work with them to cope with the
experience and support them to go on with their lives. Instead, we isolate them
and dose them up with the latest brand of sedative. The liquid straightjacket has
replaced its physical predecessor. Being on such medication is like thinking
through treacle. I remember wondering: How am I expected to recover from this?
To put it crudely: as a society we try to tum distressed and confused people into
passive drug-dependent victims. This is not to mention the hundreds of adverse
effects on the body that these chemicals cause. The widespread, long-term use
of powerful drugs in a heavy-handed way continues to disable permanently
thousands who have sought help from psychiatry." (The Independent on Sunday,
United Kingdom, Sunday 30 June 2002, page 20).
Over the past number of years, psychiatrists have been striving to improve the
image of our discipline in the eyes of both the rest of the medical fraternity as
well as the public. Whether we agree with the notion or not, we are seen to be
capable of "controlling the minds" of those whom we serve. Yet, we often claim to
be the moral guardians of ethical values in medicine. If this were to be the case,
we should continually be re-examining ourselves to see whether we are meeting
the standards that we set for others. Why would an article like the one quoted
above appear in a highly respected, international newspaper? We could write it
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off as the misguided ramblings of an obsessed fringe group. However, it may
reflect the perception of the public at large.
We are certainly in a unique position within medicine: whereas a patient with
cancer may choose to refuse treatment, even if we know that the choice may be
wrong, the patient with psychosis in our country (and many others) has no such
luxury. He/she may be incarcerated without consent, and is often treated against
his/her will. This, we proclaim, is for the greater good. We have thus become
both the all-powerful treating agent, whilst at the same time claiming for
ourselves the title of defender of those who cannot speak for themselves. We
should treat this paradoxical position with the greatest circumspection. It is a
great responsibility.
Up to the middle of the previous century, psychiatry was a custodial profession,
and treatment was not a real option. Today, we have a myriad of treatments
available, many of which are chemical in nature. It has, in some ways, made life
easier for the psychiatrist, who can now offer his patient real treatment, with the
possibility of return to pre-morbid functioning. On another level, though, there
may be truth in the perception that the chemical option has provided an "easy
way out" and has robbed psychiatry of many of the things that it is supposed to
stand for: close interaction with patients and family, empathy, warmth,
unconditional acceptance. So often today, we will prescribe a pill for any
disturbance in behaviour, lest a patient becomes dangerous or stays in hospital
too long. We have, in many ways, not progressed from the time when "madmen"
were banned from the cities of the middle ages, to live like lepers outside the
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walls of civilization. The only difference is that, with so-called "defensive
medicine" the only safe option available, we use chemicals to remove people
from society, so-called "defensive medicine".
Does this imply that treatment with medication is bad? Certainly not, and we
should guard against oversimplified and dichotomous thinking of "all good" or "all
bad". These medications offer us magnificent, but limited options. Like all
medications, be they painkillers or antibiotics, they have a therapeutic window.
As long as we stay within this window, the medication is, for most people, a
godsend that will relieve their suffering. However rampant, unrestricted use of
huge doses of psychiatric medication will have the same effect as with any other
medication: side effects and toxicity.
Antipsychotic medication is one of the wonders of modem medicine. We should
treat it with the respect it deserves and use it with great care. There is now ample
evidence that these medications may be harmful if given unnecessarily or in
excessive doses. The first rule of medicine remains: First, do no harm.
We believe that the value of the study lies therein that it neither vilifies nor
glorifies haloperidol - it shows it for what it is: a chemical compound with
excellent, but limited treatment abilities. When used carefully and in appropriate
doses, it may help many people achieve better quality of life. But in doses that
are even slightly too high, it turns into a toxic compound that causes parkinsonian
side effects, dystonia, akathisia, hyperprolactinaemia and tardive dyskinesia.
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It seems that patients from our population may be even more susceptible to the
side effects of this medication. Achieving these "perfect" doses therefore requires
a considerable amount of time, but more particularly, skill. Unfortunately, most
people who prescribe these medications possess neither. It is therefore a great
irony that the very people who could perhaps benefit the most from the second-
generation antipsychotic medications are the ones who are denied access to
them.
While we have, for various reasons, no access to the second-generation
antipsychotics, it is imperative that we use the medications at our disposal with
the utmost care, particularly in patients who have a first episode of psychosis.
We believe that we have provided considerable evidence that, at ultra-low doses
(below 2mg/day), haloperidol is an effective and well-tolerated antipsychotic for
the majority of subjects with a first psychotic episode. Even slightly higher doses
hold risks that our patients should not be exposed to.
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